var title_f5_42_5792="Postoperative liver shift CT";
var content_f5_42_5792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postpneumonectomy shift of the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Chest CT demonstrates the postoperative change in location of the liver, showing the potential risk of hepatic injury with blind chest tube or needle placement into the postpneumonectomy space. The liver (closed arrow) abuts the chest wall; the open arrow denotes fluid in the postpneumonectomy space.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Irwin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5792=[""].join("\n");
var outline_f5_42_5792=null;
var title_f5_42_5793="Barbell stud";
var content_f5_42_5793=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barbell stud",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of R Michelle Schmidt, MD and Myrna L Armstrong, EdD, RN, FAAN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5793=[""].join("\n");
var outline_f5_42_5793=null;
var title_f5_42_5794="Pancreatic stone removal";
var content_f5_42_5794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Removal of a stone fragment from the pancreatic duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic imaging showing a fragment of a pancreatic duct stone being removed following pancreatoscopy with lithotripsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5794=[""].join("\n");
var outline_f5_42_5794=null;
var title_f5_42_5795="Ultrasound image of normal three vessel cord";
var content_f5_42_5795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=68\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=68\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound image of a normal three vessel umbilical cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross sectional image of the umbilical cord at 18 weeks of gestation shows two arteries (white arrows) and one vein (red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5795=[""].join("\n");
var outline_f5_42_5795=null;
var title_f5_42_5796="Emedastine: Patient drug information";
var content_f5_42_5796=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Emedastine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/20/323?source=see_link\">",
"     see \"Emedastine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emadine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691838",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702016",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to emedastine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat contact lens irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696951",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wear contact lenses if your eyes are red.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if solution changes color.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12413 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5796=[""].join("\n");
var outline_f5_42_5796=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164561\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014238\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014237\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014242\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014243\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014245\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014240\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014241\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014246\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014247\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/20/323?source=related_link\">",
"      Emedastine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_42_5797="Benign teratoma";
var content_f5_42_5797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benign ovarian teratoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross intraoperative photograph of a benign teratoma, which in this case contains a mandible (area of forceps).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mitchel Hoffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5797=[""].join("\n");
var outline_f5_42_5797=null;
var title_f5_42_5798="Q-switched laser skin whitening";
var content_f5_42_5798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin whitening after Q-switched laser treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo demonstrates the expected skin whitening effect that appears immediately after treatment with a Q-switched laser.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5798=[""].join("\n");
var outline_f5_42_5798=null;
var title_f5_42_5799="Popliteal artery A gram";
var content_f5_42_5799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Arteriogram of the popliteal artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 561px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior view of an angiogram of the popliteal artery and branches. Note that the circumflex fibular artery supplies a hypervascular lesion in the popliteal fossa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Uflacker, R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5799=[""].join("\n");
var outline_f5_42_5799=null;
var title_f5_42_5800="Hemarthrosis";
var content_f5_42_5800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemarthrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/42/5800/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5800/contributors\">",
"     Peter A Nigrovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/42/5800/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5800/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/42/5800/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5800/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/42/5800/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding into a joint is referred to as hemarthrosis and is an important cause of monoarticular joint pain and swelling. Hemarthrosis may be suspected on the basis of a suggestive history, physical examination, or imaging studies, but definitive diagnosis usually requires joint aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21239?source=see_link\">",
"     \"Joint aspiration or injection in children: Indications, technique, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     JOINT ASPIRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial fluid obtained from a patient with a hemarthrosis may appear red, pink, or brown. Other abnormalities of the fluid may be noted that depend upon the cause of the bleeding. As an example, the presence of lipid globules strongly suggests an intraarticular fracture, resulting in leakage of marrow fat into the synovial fluid. A true bloody effusion usually fails to clot due to chronic fibrinolysis, while blood from a traumatic aspiration generally does coagulate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the aspiration is not bloody initially, but fresh blood appears after some synovial fluid has been withdrawn, the most likely cause is a traumatic arthrocentesis. In this case, centrifugation of the specimen is useful. A serous appearance of the synovial fluid supernatant suggests that fresh blood has been admixed with previously nonbloody fluid. The aspirate from a patient with hemarthrosis will generally exhibit xanthochromia from lysis of the resident erythrocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAUSES OF HEMARTHROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broad categories of disorders that may result in hemarthrosis include trauma, bleeding disorders, neurologic deficits, arthritis, neoplasms, vascular damage, and other miscellaneous causes (",
"    <a class=\"graphic graphic_table graphicRef80811 \" href=\"UTD.htm?18/47/19196\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Traumatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries are among the most common causes of hemarthrosis. In patients with normal sensation, and without a bleeding diathesis, the joint trauma is generally remembered. The pain is often severe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/2\">",
"     2",
"    </a>",
"    ]. However, pain may be minimal or absent immediately following the event. Patients with impaired sensation from neuropathy or myelopathy may have little or no pain despite the presence of a fracture.",
"   </p>",
"   <p>",
"    Following a major injury with intraarticular bleeding, synovial fluid rapidly accumulates. The accumulation of bloody fluid is due to soft tissue injury or to bone or osteochondral fracture. Serious ligamentous, osseous, or cartilage damage may be suspected when joint swelling occurs within 12 hours after trauma, though swelling is present within two hours in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Knee injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knee is a frequent site of injury and evaluation for internal derangement is an important part of the evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    .) The most common mechanism of injury in patients with acute hemarthrosis of the knee is forced twisting of the loaded joint [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of cases of posttraumatic hemarthrosis of the knee are associated with ligamentous and meniscal damage (",
"    <a class=\"graphic graphic_table graphicRef65058 \" href=\"UTD.htm?6/21/6491\">",
"     table 2",
"    </a>",
"    ). Anterior cruciate ligament (ACL) tears are most common, occurring in approximately 70 percent of patients with posttraumatic hemarthrosis of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/3\">",
"     3",
"    </a>",
"    ]. Meniscal tears occur in 10 percent of patients, one-half of whom also have an ACL tear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/2\">",
"     2",
"    </a>",
"    ]. Patellar subluxation or dislocation occurs in 10 to 15 percent of patients, and osteochondral fracture fragments are found in 2 to 5 percent. Other lesions, such as posterior cruciate ligament injuries and capsule tears, occur in about 5 percent.",
"   </p>",
"   <p>",
"    Tenderness to palpation of the medial or lateral joint lines or the patella can indicate the site of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinical tests for stability are performed with varus (for the lateral collateral ligament), valgus (for the medial collateral ligament), anterior (drawer test, for the anterior cruciate ligament), and posterior stress (posterior draw or sag test, for the posterior cruciate ligament) (",
"    <a class=\"graphic graphic_picture graphicRef69222 graphicRef77592 graphicRef73257 \" href=\"UTD.htm?29/14/29928\">",
"     picture 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The initial imaging technique of choice is plain film radiography of the involved joint and adjacent bones. For the knee, anterior-posterior, lateral, patellar, and tunnel views are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/5\">",
"     5",
"    </a>",
"    ]. If a fracture is strongly suspected but radiographs are negative, computed tomography (CT) may aid in diagnosis. Magnetic resonance imaging (MRI) provides helpful information about ligamentous and cartilaginous structures that are not typically visible with plain radiographs or CT.",
"   </p>",
"   <p>",
"    Arthroscopic evaluation of the knee provides an alternative approach to assessing the severity of knee damage when injury is accompanied by hemarthrosis. In a prospective study, all injured knees that had a traumatic hemarthrosis with little or no instability on clinical examination underwent arthroscopy and examination under anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/6\">",
"     6",
"    </a>",
"    ]. One-third of the knees had slight or no pain at the time of the injury. Some degree of disruption of the ACL of the involved knee was found in 71 percent of the patients examined, while a torn meniscus was present in 47 percent. A meniscal tear was frequently associated with injuries of varying severity to other joint structures.",
"   </p>",
"   <p>",
"    Other damage found during arthroscopy and examination under anesthesia included minor ligament sprains without laxity, major associated ligament injury, and femoral cartilage fractures or surface defects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/6\">",
"     6",
"    </a>",
"    ]. When examined without anesthesia, some patients with documented ACL tears did not have a positive drawer sign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lipohemarthrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipohemarthrosis is the presence of fat and blood in a joint cavity. It is usually caused by intracapsular fractures or extensive intraarticular soft tissue injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/3\">",
"     3",
"    </a>",
"    ]. Lipohemarthrosis can be detected during arthrocentesis, by CT scan or MRI,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plain radiology [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. While a single fluid-fluid level on cross-table plain radiographs is suggestive of lipohemarthrosis, this finding may occur due to separation of intraarticular cellular and fluid components following intraarticular bleeding without the presence of fat in joint fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/8\">",
"     8",
"    </a>",
"    ]. The finding of a double fluid-fluid level is more specific for lipohemarthrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/7\">",
"     7",
"    </a>",
"    ]. The diagnosis can be confirmed by ultrasonography in a minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Minimal injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;If hemarthrosis occurs after minimal trauma, coagulation disorders, such as hemophilia, an acquired inhibitor to factor VIII, or other disorder of blood clotting should be suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Diagnostic approach'",
"    </a>",
"    .) When hemarthrosis following minimal trauma is not due to a bleeding diathesis, the most commonly documented injuries are ACL and meniscal tears [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/8,11\">",
"     8,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Postoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent postoperative hemarthrosis has been described in patients following total knee arthroplasty and has been attributed to the development of intracapsular vascular tissue subsequent to joint replacement. In addition, hemarthrosis has occurred after lateral releases and after arthroscopy. This is considered an unusual complication of such surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nontraumatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of hereditary, acquired, and iatrogenic bleeding disorders can result in hemarthrosis. Other potential causes are neurologic, infectious, and vascular diseases, arthritis, particularly osteoarthritis with associated chondrocalcinosis, and neoplasms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bleeding disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding disorders should be considered when hemarthrosis occurs with minimal or no recollected trauma. Questions about bleeding during or after surgical or dental procedures, use of anticoagulant medications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] or rarely thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and diet may help uncover the presence of a bleeding diathesis or its cause. Initial laboratory tests include a complete blood count, prothrombin time (PT), and activated partial thromboplastin time (aPTT) (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 3",
"    </a>",
"    ). A bleeding time may be helpful if the history or physical examination suggests a platelet disorder; however, joint bleeding is typically seen with deficiencies in coagulation factors, rather than platelets (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 4",
"    </a>",
"    ). Unexplained abnormalities of any of these tests require further investigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemophilic arthropathy &mdash; Hemarthrosis is the most common musculoskeletal manifestation of hemophilia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/20\">",
"       20",
"      </a>",
"      ]. Severe hemophilia (defined as less than 1 percent of normal factor activity) causes hemarthrosis in 75 to 90 percent of patients. The first attack usually occurs between two or three years of age. The knee is the most common joint involved, followed by the elbow, ankle, hip, and shoulder. Bilateral involvement is not uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical manifestations and diagnosis of hemophilia\", section on 'Hemophilic arthropathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three forms of hemarthrosis are recognized: acute, subacute, and chronic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In acute hemarthrosis, the affected joint is painful, swollen, and warm, and range of motion is reduced. The clinical manifestations vary by age. In infants, early signs of bleeding include irritability and decreased use of the affected limb. In older children and adults, hemarthrosis is manifested by prodromal stiffness and, in some patients, by a characteristic warm sensation, which is followed by acute pain and swelling. One joint is usually affected at a time, but multiple bleeding sites are not uncommon. Symptoms respond rapidly to plasma and factor replacement, and as the effusion is reabsorbed, mobility returns.",
"     </li>",
"     <li>",
"      Untreated hemorrhage can lead to intraarticular damage in the subacute stage. In this stage, toxic effects of blood products lead to synovial hypertrophy, fibrosis, and impaired joint movement. Despite marked internal derangement, joint pain is not prominent at this time.",
"     </li>",
"     <li>",
"      Repeated attacks or persistent hemorrhage for more than six months leads to chronic disabling arthropathy with symptoms sometimes mimicking osteoarthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histopathology of hemophilic arthropathy is complex [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/21\">",
"     21",
"    </a>",
"    ]. In early disease, the histology reveals synovial hypertrophy and fibrosis, changes similar to rheumatoid arthritis. Late disease is characterized by disruption of cartilage and by subchondral bone cyst formation. Cyst formation appears to reflect the combined effects of degeneration and interosseous bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Cartilage and bone destruction in affected patients appears to be the result of direct toxic effects of blood products, mechanical effects, and cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/22\">",
"     22",
"    </a>",
"    ]. Iron, in the form of ferric citrate, stimulates human fibroblast like synovial cells to proliferate in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/25\">",
"     25",
"    </a>",
"    ]. In vitro data suggest that blood can be toxic to human cartilage after as little as two days, though whether this is also true of the living joint is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/26\">",
"     26",
"    </a>",
"    ]. Growing cartilage is most susceptible to blood-induced damage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, children should be treated aggressively to minimize joint injury.",
"   </p>",
"   <p>",
"    Treatment of hemarthrosis in the setting of hemophilia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H29#H29\">",
"     \"Treatment of hemophilia\", section on 'Hemarthrosis of peripheral joints'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H31#H31\">",
"     \"Treatment of hemophilia\", section on 'Hemarthrosis of the hip and iliopsoas bleeds'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiologically, five stages of hemophilic arthropathy are recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1: Soft tissue swelling &mdash; This is characterized by swelling secondary to direct bleeding, both into the joint and into the adjacent tissues.",
"     </li>",
"     <li>",
"      Stage 2: Osteoporosis &mdash; The second stage is characterized by the development of osteoporosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epithelial overgrowth secondary to inflammatory hyperemia, especially marked in the knee and elbow.",
"     </li>",
"     <li>",
"      Stage 3: Osseous lesions &mdash; The third stage is characterized by disorganization of the joint with overgrowth of the epiphysis, squaring of the patella, widening of the articular notch of the knee and the trochlea of the ulna; the articular cartilage remains intact.",
"     </li>",
"     <li>",
"      Stage 4: Cartilage destruction &mdash; The fourth stage is characterized by destruction and secondary joint space narrowing.",
"     </li>",
"     <li>",
"      Stage 5: Joint disorganization &mdash; The fifth stage is due to chronic disease that leads to complete loss of cartilage spaces, and considerable bony erosion and irregularity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    X-ray assessment of hemophilic arthropathy tends to underestimate the joint destruction. MRI and CT allow early evaluation of the joint damage, subchondral cysts, and cartilage or synovial lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemarthrosis of the knee can occur as a result of osteoarthritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated degenerative tears of a meniscus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Neurologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes of hemarthrosis can occur in patients with reflex sympathetic dystrophy and Charcot's joints due to neuropathy with impaired position sensation and protective reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=see_link\">",
"     \"Diabetic neuropathic arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemarthrosis may occur without associated trauma in patients with bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Vascular disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular fragility due to vitamin C deficiency may lead to hemarthrosis and subperiosteal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link&amp;anchor=H54#H54\">",
"     \"Overview of water-soluble vitamins\", section on 'Vitamin C (ascorbic acid)'",
"    </a>",
"    .) Peripheral arterial aneurysms may rupture, resulting in intraarticular hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neoplasms most often associated with hemarthrosis are generally benign. Two important types are synovial hemangiomas and pigmented villonodular synovitis. Malignant tumors, both metastatic and those arising de novo in or near a joint, can lead to bloody effusions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Synovial hemangioma &mdash; A synovial hemangioma is a benign vascular tumor that can occur in a joint, usually the knee. Children are more likely to have intraarticular hemangiomas than adults. Affected patients present with a recurrent painful monoarticular hemarthrosis, usually affecting the knee [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/32\">",
"       32",
"      </a>",
"      ]. Recurrent swelling due to hemarthrosis and intermittent pain can be present long before the diagnosis is made.",
"      <br/>",
"      <br/>",
"      Synovial hemangiomas may be congenital, appearing as solitary neoplasms that infiltrate local tissue and adjacent neurologic structures. Whether congenital or not, the margins of the mass are typically composed of both large and small vessels. Despite their vascular origin, hemangiomas do not metastasize or undergo malignant transformation. Pathologic examination of hemangiomas shows spaces of various sizes, ranging from capillaries to cavernous sinusoids, which are lined by endothelium.",
"     </li>",
"     <li>",
"      Pigmented villonodular synovitis &mdash; Pigmented villonodular synovitis (PVNS) is a slow growing, benign, but locally invasive tumor of the synovium. It most commonly involves the knee, but can also occur in the hip, ankle, and elbow. Episodic acute attacks of pain and swelling are associated with spontaneous hemarthrosis. Most patients with knee involvement have difficulty in ambulation, and may experience locking and catching of the joint. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=see_link&amp;anchor=H5#H5\">",
"       \"Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone\", section on 'Pigmented villonodular synovitis/tenosynovial giant cell tumor'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The synovial fluid classically is dark brown or hemorrhagic. A synovial biopsy may be diagnostic. The histopathology of PVNS can mimic rheumatoid arthritis, but PVNS affects few joints and rarely in a symmetrical fashion. It usually presents as a monoarticular hemarthrosis and it may exist in nodular or diffuse form [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The diffuse form is characterized by a history of swelling that is not preceded by trauma. On physical examination the majority of patients have distension of the suprapatellar pouch and a large effusion. As many as 40 percent may have a palpable diffuse synovial mass. This can be accompanied by periarticular erosions on plain radiographs; the disease may be active or inactive. The nodular form is less common and does not show the same destructive changes as the diffuse form. It can cause recurrent hemarthrosis, but the aspirate may be of normal color and not show the classic changes or radiographic findings.",
"      <br/>",
"      <br/>",
"      The most common feature of PVNS on MRI is the presence of intraarticular nodules or masses. MRI findings are very useful in the diagnosis of PVNS, because hemosiderin in the tissues renders PVNS \"dark\" on all MRI sequences due to a characteristic lack of signal on both T1 and T2 images. Treatment with arthroscopic synovectomy may be indicated for the nodular form or for the inactive form of diffuse disease. Systemic administration of TNF antagonists was reportedly beneficial in one case [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=see_link&amp;anchor=H5#H5\">",
"       \"Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone\", section on 'Pigmented villonodular synovitis/tenosynovial giant cell tumor'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hemarthrosis can be divided into interventions that are generally useful for any patient with an acute hemarthrosis and more specific treatment directed toward the underlying disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immobilization, particularly with acute posttraumatic hemarthrosis, ice, and compression are important first-aid measures. Potent analgesics may be required while the diagnostic evaluation proceeds. Aspiration itself may provide some relief of pain. While recurrent hemarthroses risk joint injury, isolated episodes of bleeding into the joint are generally benign; lavage is not indicated.",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory drugs (NSAIDs) should be avoided until the results of tests of the coagulation cascade are completed. Use of a selective cyclooxygenase-2 (COX-2) inhibitor, rofecoxib (no longer available), was reported in a patient with hemophilic arthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/35\">",
"     35",
"    </a>",
"    ]. Since the selective COX-2 inhibitors do not interfere with platelet function and may be less likely to cause gastroduodenal damage than nonselective NSAIDs, this approach has some appeal for treating chronic joint pain in those with clotting factor deficiencies. However, until more data are available on the safety of selective COX-2 inhibitors, it is prudent to avoid their use in patients with known ischemic heart disease or those at high risk for myocardial infarction or stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link&amp;anchor=H2#H2\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Ischemic cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Specific",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment can be employed when a definite cause for the hemarthrosis can be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     After major trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with major trauma are at risk for significant bone and soft tissue injuries. Complete immobilization of the involved joint is prudent until radiographs have been obtained. If there is evidence of a fracture or suspicion of an internal derangement, orthopedic consultation should be considered. Although not all intraarticular fractures require operative intervention, the patient and radiographic findings should be discussed with someone experienced in fracture care. Ligamentous and meniscal injuries do not generally require immediate operative intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hemarthrosis after minor or no trauma are, as discussed previously, likely to have some type of bleeding disorder, most often hemophilia or administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Patients with known clotting factor deficiency are appropriately treated with replacement therapy. At the first indication of bleeding in hemophilia, the patient or parent should infuse clotting factor at a dose that achieves a level of 40 to 50 percent of normal. A short course of oral glucocorticoids may also speed resolution of swelling and help reduce joint pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/36\">",
"     36",
"    </a>",
"    ]. Increased clotting factor replacement for a period of time following the acute hemarthrosis is recommended to prevent recurrent bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H29#H29\">",
"     \"Treatment of hemophilia\", section on 'Hemarthrosis of peripheral joints'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H31#H31\">",
"     \"Treatment of hemophilia\", section on 'Hemarthrosis of the hip and iliopsoas bleeds'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemarthrosis usually responds well if treated early, eg, with appropriate factor replacement beginning at the patient's home. Recurrent hemarthrosis can often be ameliorated by chemical or mechanical synovectomy. However, chronic hemophilic arthropathy remains distressingly common. Scheduled factor replacement should be considered in children with severe hemophilia to help prevent this complication of recurrent hemarthrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of hemophilia\", section on 'Prophylactic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Synovectomy, when required, can be performed arthroscopically, as an open surgical procedure, or through the use of injected radioactive isotopes. More advanced disease may lead to total joint arthroplasty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=see_link\">",
"     \"Synovectomy for inflammatory arthritis of the knee\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H35#H35\">",
"     \"Treatment of hemophilia\", section on 'Chronic hemarthrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to patients treated with anticoagulation is variable. If the patient is not at immediate risk of thromboembolism, as with chronic atrial fibrillation in the absence of valvular heart disease, it may be helpful to replete clotting factors with fresh frozen plasma. Patients who are high risk, such as those with prosthetic heart valves, may be managed by reducing the intensity of anticoagulation to the lower limit of the therapeutic range while providing analgesia and joint rest. If these options are not feasible, temporary immobilization, analgesics, and joint aspiration to reduce pressure may be the only treatment that can be provided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Postoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Revision arthroplasty may be necessary in patients with recurrent postoperative hemarthrosis. In one reported case, angiographically guided embolization controlled recurrent bleeding into the knee in a patient who required chronic anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Aneurysms",
"    </span>",
"    &nbsp;&mdash;&nbsp;If surgical treatment is not feasible, endovascular treatment with arterial embolization may also be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5800/abstract/31,39\">",
"     31,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Benign tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopic or surgical synovectomy is the treatment of choice to prevent recurrent episodes of hemarthrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=see_link\">",
"     \"Synovectomy for inflammatory arthritis of the knee\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167399909\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemarthrosis, bleeding into a joint from any of a variety of causes (",
"      <a class=\"graphic graphic_table graphicRef80811 \" href=\"UTD.htm?18/47/19196\">",
"       table 1",
"      </a>",
"      ), results in monarticular pain and swelling. Diagnosis usually requires joint aspiration, which reveals red, pink, or brown synovial fluid. Other abnormalities of the fluid depend upon the cause of the bleeding. A true bloody effusion usually fails to clot due to chronic fibrinolysis, while blood from a traumatic aspiration generally does coagulate. Traumatic arthrocentesis is most likely if the aspiration is not bloody initially, but fresh blood appears after some synovial fluid has been withdrawn. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Causes of hemarthrosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Joint aspiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injuries are among the most common causes of hemarthrosis. The pain is often severe, but may be minimal or absent immediately following the event. Patients with impaired sensation from neuropathy or myelopathy may have little or no pain despite the presence of a fracture. The rapid accumulation of bloody fluid that follows a major injury with intraarticular bleeding is due to soft tissue injury or to bone or osteochondral fracture. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Traumatic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The knee is a frequent site of injury, and evaluation for internal derangement is an important part of the evaluation. The most common mechanism of injury in patients with acute hemarthrosis of the knee is forced twisting of the loaded joint. The initial imaging technique of choice is plain film radiography. If a fracture is strongly suspected but radiographs are negative, computed tomography may aid in diagnosis. Magnetic resonance imaging provides helpful information about ligamentous and cartilaginous structures. Arthroscopic evaluation of the knee may be helpful in some patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Knee injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional concerns in patients with traumatic hemarthrosis include lipohemarthrosis, recurrent postoperative hemarthrosis following total knee arthroplasty, and coagulation disorders, which should be suspected in patients in whom hemarthrosis occurs after minimal trauma. When hemarthrosis following minimal trauma is not due to a bleeding diathesis, the most commonly documented injuries are ACL and meniscal tears. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lipohemarthrosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Minimal injuries'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Postoperative'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of hereditary, acquired, and iatrogenic bleeding disorders can result in hemarthrosis. Bleeding disorders should be considered when hemarthrosis occurs with minimal or no recollected trauma. Hemarthrosis is typically seen with deficiencies in coagulation factors, rather than platelets (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"       table 4",
"      </a>",
"      ). Three forms of hemarthrosis due to hemophilia and other coagulopathies are recognized: acute, subacute, and chronic; and five stages of hemophilic arthropathy have been identified. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bleeding disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential causes of hemarthrosis other than bleeding disorders include neurologic, infectious, and vascular diseases; arthritis, particularly osteoarthritis with associated chondrocalcinosis; and neoplasms, including pigmented villonodular synovitis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Nontraumatic'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Osteoarthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Neurologic disorders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Septic arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Vascular disorders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of hemarthrosis can be divided into interventions that are generally useful for any patient with an acute hemarthrosis and more specific treatment directed toward the underlying disorder. Treatments of general benefit include immobilization, ice, and compression initially; analgesia; and arthrocentesis. Nonsteroidal antiinflammatory drugs that interfere with platelet function should be avoided. Specific treatment can be employed when a definite cause for the hemarthrosis can be identified. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'General'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Specific'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'After major trauma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Postoperative'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Aneurysms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Benign tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with known clotting factor deficiency are appropriately treated with replacement therapy. Hemarthrosis usually responds well if treated early in such patients. Recurrent hemarthrosis can often be ameliorated by synovectomy. More advanced disease may lead to total joint arthroplasty. The approach to patients treated with anticoagulation is variable, depending upon the risk of reduced anticoagulation therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Coagulopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/1\">",
"      Dougados M. Synovial fluid cell analysis. Baillieres Clin Rheumatol 1996; 10:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/2\">",
"      Baker CL. Acute hemarthrosis of the knee. J Med Assoc Ga 1992; 81:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/3\">",
"      Maffulli N, Binfield PM, King JB, Good CJ. Acute haemarthrosis of the knee in athletes. A prospective study of 106 cases. J Bone Joint Surg Br 1993; 75:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/4\">",
"      Visuri T, Koskenvuo M, Dahlstr&ouml;m S. Hemarthrosis of the clinically stable knee due to sports and military training in young recruits: an arthroscopic analysis. Mil Med 1993; 158:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/5\">",
"      Allum R. The management of acute traumatic haemarthrosis of the knee. Br J Hosp Med 1997; 58:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/6\">",
"      Bomberg BC, McGinty JB. Acute hemarthrosis of the knee: indications for diagnostic arthroscopy. Arthroscopy 1990; 6:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/7\">",
"      Ryu KN, Jaovisidha S, De Maeseneer M, et al. Evolving stages of lipohemarthrosis of the knee. Sequential magnetic resonance imaging findings in cadavers with clinical correlation. Invest Radiol 1997; 32:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/8\">",
"      Lugo-Olivieri CH, Scott WW Jr, Zerhouni EA. Fluid-fluid levels in injured knees: do they always represent lipohemarthrosis? Radiology 1996; 198:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/9\">",
"      Bianchi S, Zwass A, Abdelwahab IF, et al. Sonographic evaluation of lipohemarthrosis: clinical and in vitro study. J Ultrasound Med 1995; 14:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/10\">",
"      Ames PR, Maffulli N, Capasso G, Brancaccio V. Minimal trauma knee hemarthrosis. Bull Hosp Jt Dis 1996; 54:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/11\">",
"      Lu KH, Hsiao YM, Lin ZI. Arthroscopy for acute knee haemarthrosis in road traffic accident victims. Injury 1996; 27:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/12\">",
"      Worland RL, Jessup DE. Recurrent hemarthrosis after total knee arthroplasty. J Arthroplasty 1996; 11:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/13\">",
"      Ballard WT, Clark CR, Callaghan JJ. Recurrent spontaneous hemarthrosis nine years after a total knee arthroplasty. A presentation with pigmented villonodular synovitis. J Bone Joint Surg Am 1993; 75:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/14\">",
"      Oishi CS, Elliott ML, Colwell CW Jr. Recurrent hemarthrosis following a total knee arthroplasty. J Arthroplasty 1995; 10 Suppl:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/15\">",
"      Schneider T, Fink B, Abel R, et al. Hemarthrosis as a major complication after arthroscopic subcutaneous lateral retinacular release: a prospective study. Am J Knee Surg 1998; 11:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/16\">",
"      Wild JH, Zvaifler NJ. Hemarthrosis associated with sodium warfarin therapy. Arthritis Rheum 1976; 19:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/17\">",
"      Jaffer AM, Schmid FR. Hemarthrosis associated with sodium warfarin. J Rheumatol 1977; 4:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/18\">",
"      Birnbaum Y, Stahl B, Rechavia E. Spontaneous hemarthrosis following thrombolytic therapy for acute myocardial infarction. Int J Cardiol 1993; 40:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/19\">",
"      Finlayson J, Dunsmuir RA. Haemarthrosis following thrombolytic therapy for acute myocardial infarction. Injury 1997; 28:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/20\">",
"      Lan HH, Eustace SJ, Dorfman D. Hemophilic arthropathy. Radiol Clin North Am 1996; 34:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/21\">",
"      Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977; 59:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/22\">",
"      Roosendaal G, Vianen ME, Marx JJ, et al. Blood-induced joint damage: a human in vitro study. Arthritis Rheum 1999; 42:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/23\">",
"      Rodriguez-Merchan EC. The destructive capabilities of the synovium in the haemophilic joint. Haemophilia 1998; 4:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/24\">",
"      Roosendaal G, Tekoppele JM, Vianen ME, et al. Articular cartilage is more susceptible to blood induced damage at young than at old age. J Rheumatol 2000; 27:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/25\">",
"      Wen FQ, Jabbar AA, Chen YX, et al. c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide. Blood 2002; 100:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/26\">",
"      Jansen NW, Roosendaal G, Bijlsma JW, et al. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: an in vitro study. Arthritis Rheum 2007; 56:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/27\">",
"      Feldman BM. Preventing joint damage from hemophilia. J Rheumatol 2000; 27:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/28\">",
"      Kawamura H, Ogata K, Miura H, et al. Spontaneous hemarthrosis of the knee in the elderly: etiology and treatment. Arthroscopy 1994; 10:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/29\">",
"      Braverman DL, Kern HB, Nagler W. Recurrent spontaneous hemarthrosis associated with reflex sympathetic dystrophy. Arch Phys Med Rehabil 1998; 79:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/30\">",
"      Mowad CM, Howe KL, Guzzo CA. Unexplained hemothorax, hemarthrosis, and palpable purpura. Hosp Pract (Off Ed) 1995; 30:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/31\">",
"      Klein GE, Raith J, Passler J, et al. Spontaneous recurrent hemarthrosis of the knee joint: endovascular treatment of a ruptured aneurysm with platinum microcoils. A case report. J Bone Joint Surg Am 1997; 79:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/32\">",
"      Wirth T, Rauch G, R&uuml;schoff J, Griss P. Synovial haemangioma of the knee joint. Int Orthop 1992; 16:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/33\">",
"      Frassica FJ, Bhimani MA, McCarthy EF, Wenz J. Pigmented villonodular synovitis of the hip and knee. Am Fam Physician 1999; 60:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/34\">",
"      Kroot EJ, Kraan MC, Smeets TJ, et al. Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis 2005; 64:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/35\">",
"      Bragad&oacute;ttir G, Onundarson PT. Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy. Haemophilia 2002; 8:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/36\">",
"      Kisker CT, Burke C. Double-blind studies on the use of steroids in the treatment of acute hemarthrosis in patients with hemophilia. N Engl J Med 1970; 282:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/37\">",
"      Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/38\">",
"      Katsimihas M, Robinson D, Thornton M, Langkamer VG. Therapeutic embolization of the genicular arteries for recurrent hemarthrosis after total knee arthroplasty. J Arthroplasty 2001; 16:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5800/abstract/39\">",
"      Omary R, Stulberg SD, Vogelzang RL. Therapeutic embolization of false aneurysms of the superior medial genicular artery after operations on the knee. A report of two cases. J Bone Joint Surg Am 1991; 73:1257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5605 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-90821EDB07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5800=[""].join("\n");
var outline_f5_42_5800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H167399909\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      JOINT ASPIRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAUSES OF HEMARTHROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Traumatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Knee injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lipohemarthrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Minimal injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Postoperative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nontraumatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Neurologic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Vascular disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Specific",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - After major trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Postoperative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Aneurysms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Benign tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H167399909\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5605|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/46/37600\" title=\"picture 1A\">",
"      Varus stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/37/41552\" title=\"picture 1B\">",
"      Valgus stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/19/38192\" title=\"picture 1C\">",
"      Anterior drawer test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5605|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/47/19196\" title=\"table 1\">",
"      Causes of hemarthrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/21/6491\" title=\"table 2\">",
"      Acute hemarthrosis of the knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/45/43740\" title=\"table 3\">",
"      Causes PT and PTT abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2748\" title=\"table 4\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=related_link\">",
"      Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=related_link\">",
"      Diabetic neuropathic arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21239?source=related_link\">",
"      Joint aspiration or injection in children: Indications, technique, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=related_link\">",
"      Synovectomy for inflammatory arthritis of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=related_link\">",
"      Treatment of hemophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_42_5801="Congenital erythropoietic porphyria";
var content_f5_42_5801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital erythropoietic porphyria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/42/5801/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5801/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/42/5801/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5801/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5801/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/42/5801/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5801/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5801/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/42/5801/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital erythropoietic porphyria (CEP) is an autosomal recessive inborn error of heme biosynthesis resulting from a markedly deficient activity of the cytosolic enzyme, uroporphyrinogen III synthase [UROS; EC 4.2.1.75, hydroxymethylbilane hydrolase (cyclizing)] [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The enzymatic defect in CEP causes the accumulation of the non-physiologic and pathogenic porphyrin isomers, uroporphyrin I and coproporphyrin I, leading to the clinical manifestations of CEP. It is also called G&uuml;nther disease, erythropoietic porphyria, congenital porphyria, congenital hematoporphyria, and erythropoietic uroporphyria. CEP is rare and panethnic; as of 1997, about 130 cases had been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology, diagnosis, and treatment of CEP will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/4\">",
"     4",
"    </a>",
"    ]. A general approach to the porphyrias is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENZYMOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uroporphyrinogen III synthase (UROS), previously termed uroporphyrinogen III cosynthase, catalyzes the conversion of the linear tetrapyrrole, hydroxymethylbilane (HMB), to the cyclic tetrapyrrole uroporphyrinogen III (URO III), the physiologic isomer which ultimately leads to the formation of heme (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ). This step (step 4 in the figure) (",
"    <a class=\"graphic graphic_figure graphicRef57890 \" href=\"UTD.htm?34/50/35617\">",
"     figure 2",
"    </a>",
"    ), involves inversion of the pyrrole D ring of HMB and cyclization to uroporphyrinogen III [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/5\">",
"     5",
"    </a>",
"    ]. In the absence of UROS, HMB is converted non-enzymatically to the non-physiologic porphyrin isomer, uroporphyrin I (URO I) (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ). URO I is then enzymatically converted to coproporphyrin I (COPRO I) via the activity of uroporphyrinogen decarboxylase, as in step 5 in the figure (",
"    <a class=\"graphic graphic_figure graphicRef57890 \" href=\"UTD.htm?34/50/35617\">",
"     figure 2",
"    </a>",
"    ), and cannot be metabolized further.",
"   </p>",
"   <p>",
"    In human erythrocytes, UROS and PBGD may exist in a cytosolic complex [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/6\">",
"     6",
"    </a>",
"    ], with an excess of UROS activity compared with PBGD, favoring the synthesis of URO III over URO I [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/7\">",
"     7",
"    </a>",
"    ]. Sensitive assays have been developed to measure UROS activity in erythrocytes and cultured cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Enzyme properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;UROS has been purified from plants and animals, including spinach, Euglena gracilis, Escherichia coli, and rat liver [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/9\">",
"     9",
"    </a>",
"    ]. Human UROS has been purified to homogeneity from erythrocytes and has been shown to be a monomeric protein with an apparent molecular weight of 29.5 kD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/6\">",
"     6",
"    </a>",
"    ]. The purified enzyme had a specific activity of over 300,000",
"    <span class=\"nowrap\">",
"     nmole/hr",
"    </span>",
"    per mg of protein, an isoelectric point of 5.5, and was remarkably thermolabile",
"    <span class=\"nowrap\">",
"     (t1/2",
"    </span>",
"    at 60&ordm;C of approximately 1 minute). The enzyme's pH optimum was 7.4 and the Km for hydroxymethylbilane was 5 to 20 mM. The enzyme is activated by Na+, K+, Mg2+, and Ca2+ and inhibited by Cd2+, Cu2+, Hg2+, and Zn2+.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     The UROS gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The full-length cDNA encoding human UROS has been isolated, sequenced, and expressed in E. coli [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/10\">",
"     10",
"    </a>",
"    ]. The cDNA is 1296 bp with 5' and 3' untranslated regions of 196 bp and 302 bp, respectively, and an open reading frame of 798 bp that encodes a polypeptide of 265 amino acids. Using the cDNA as a probe, a single UROS gene was assigned to the narrow chromosomal region 10q25.3-26.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/11\">",
"     11",
"    </a>",
"    ]. Analysis of the UROS genomic sequence revealed 10 exons; the sequence of each exon-intron junction has been determined.",
"   </p>",
"   <p>",
"    Comparison of the human and mouse cDNAs and the predicted amino acid sequences revealed 80.5 percent nucleotide and 77.8 percent amino acid identity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The murine gene was localized to a narrow region on mouse chromosome 7 within 1.5 cM of Oat, which is syntenic with the localization of the human gene on chromosome 10q25.3-26.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mutations in CEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of the full-length cDNA and genomic sequence has facilitated the identification of the molecular lesions causing CEP. To date, a variety of mutations that cause CEP have been identified in the UROS gene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. These include missense and nonsense mutations, large and small deletions and insertions, splicing defects and intronic branch point mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/20-24\">",
"     20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of the 18 known single base changes, four (A66V, A104V, T228M, and G225S), occurred at CpG dinucleotides, known hot spots for mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. All but one (V82F) of the known CEP missense mutations occurred in amino acid residues that are conserved in both mouse and human UROS polypeptide sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Among the mutations, V82F was of particular interest since it was a single base substitution (G to T) in the last nucleotide of exon 4, at the 5' donor site for intron 4, which also caused a splicing defect. A branch point mutation 23 bp upstream from the",
"    <span class=\"nowrap\">",
"     intron/exon",
"    </span>",
"    boundary of intron 8 has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients with CEP are heteroallelic (ie, compound heterozygotes) for UROS mutations. The most common mutation, C73R, was found in about 33 percent of the studied alleles. The next most common mutations were L4F and T228M (7 and 6 percent, respectively). Except for the above mutations, the other mutations have been detected in only one or a few CEP families and therefore were \"private\", or \"unique.\" Most of the mutations were panethnic in origin, having been identified in diverse racial and demographic groups. Notably, about 12 percent of the mutant alleles were undetected by sequencing the entire coding region and the intron-exon boundaries, suggesting that other sites for the mutations exist, such as those directly or indirectly affecting the gene's erythroid-specific promoter region [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genotype phenotype correlations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expression of the human UROS mutations has permitted the estimation of their relative residual activities for genotype-phenotype comparisons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/15,29-31\">",
"     15,29-31",
"    </a>",
"    ]. These ranged from essentially non-detectable to levels that were about 35 percent of the activity expressed by the normal enzyme, with only A66V and V82F alleles having activities &gt;10 percent of the mean normal expressed level. However, A66V and V82F were less stable than the expressed normal enzyme, having half-lives at 37&ordm;C of 13, 30, and 50 minutes, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For genotype-phenotype correlations, a series of CEP patients were classified as very mild to severely affected based on age, degree of hemolytic anemia, organomegaly, osteopenia, and cutaneous involvement. Homoallelism for the most common allele, C73R, was correlated with the most severe phenotype, leading to non-immune hydrops fetalis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfusion dependency from birth. Consistent with the severe phenotype of",
"    <span class=\"nowrap\">",
"     C73R/C73R",
"    </span>",
"    homozygotes, expression of the C73R allele in E. coli resulted in the detection of less than 1 percent of the UROS activity expressed by the normal allele.",
"   </p>",
"   <p>",
"    Of note, gene targeting of the mouse UROS gene resulted in death early in fetal life (ie, fetal lethal). However, the fact that human",
"    <span class=\"nowrap\">",
"     C73R/C73R",
"    </span>",
"    homozygotes are viable indicates that the mutant enzyme retains sufficient activity to produce enough heme for the biosynthesis of hemoglobin and hemoproteins. Alternatively, if the C73R mutation produces only non-functional enzyme, then the fact that affected fetuses are born suggests the possibility of another gene that is responsible for UROS activity during fetal development.",
"   </p>",
"   <p>",
"    Heteroallelism for C73R and a mutation that expresses little residual activity, such as P53L, also results in a severe or moderately severe phenotype. Patients heteroallelic for mutations that express some residual activity such as V82F (35 percent of normal activity), A104V (7.7 percent of normal activity) and A66V (14.5 percent of normal activity) have milder forms of CEP, even if the other allele is C73R or does not express detectable activity. For example, a teenage boy whose genotype was",
"    <span class=\"nowrap\">",
"     C73R/A66V",
"    </span>",
"    had only mild cutaneous involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are notable exceptions in genotype-phenotype correlations. As an example, in a Palestinian family with four siblings expressing typical and severe CEP, the affected patients and one clinically unaffected sister were shown to be homozygous for a novel S47P mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/33\">",
"     33",
"    </a>",
"    ]. UROS activity in the sister was markedly deficient, but she was entirely healthy. This finding suggests that there are modifier genes affecting disease severity in CEP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mouse model of CEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A knock-in mouse model of CEP has been created. While the complete knockout of the UROS gene was lethal, a knock-in model, which reproduced a UROS gene mutation responsible for a severe UROS deficiency in humans (P248Q missense mutant), resulted in viable animals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/35\">",
"     35",
"    </a>",
"    ]. Homozygous mice displayed extremely low UROS activity (&lt;1 percent of normal) along with erythrodontia, photosensitivity, hepatosplenomegaly, and hemolytic anemia. Subsequently, knock-in mice with 3 other missense mutations, C73R, V99A and V99L were also examined, and were shown to display similar cutaneous symptoms characteristic of the human disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, these mice appear to be a suitable model for the human CEP and should be useful for studies of disease pathogenesis and therapeutic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age at onset and clinical severity of CEP are highly variable, ranging from non-immune hydrops fetalis due to severe hemolytic anemia in utero to milder, later-onset forms, which may have only cutaneous lesions in adult life. A number of cases of adult-onset CEP have been associated with the presence of one of the myelodysplastic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases severe photosensitivity has developed soon after birth. Pink or red-brown staining of diapers due to markedly increased urinary porphyrins may be the first clue to the disease. A number of factors lead to the phenotypic variability in CEP, including :",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The amount of residual UROS activity [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The resultant degree of hemolysis and consequent stimulation of erythropoiesis",
"     </li>",
"     <li>",
"      Exposure to ultraviolet light.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, as in other porphyrias, an interplay between environmental factors and the deficient enzyme activity determines clinical expression of the disease. Overall life expectancy may be markedly diminished in more severely affected patients due to hematologic complications and an increased risk of infection. The major debilitating clinical features in patients with CEP are cutaneous photosensitivity and anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hematologic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to severe hemolysis is a feature of CEP and is accompanied by anisocytosis, poikilocytosis, polychromasia, basophilic stippling, reticulocytosis, increased nucleated red cells, absence of haptoglobin, increased unconjugated bilirubin, increased fecal urobilinogen, and increased plasma iron turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/39\">",
"     39",
"    </a>",
"    ]. Hemolysis presumably results from photochemical damage to the red cell secondary to the accumulated uroporphyrin I.",
"   </p>",
"   <p>",
"    Porphyrins, including uroporphyrins, are known to interfere with cellular redox systems, and can both inhibit and enhance free radical generation, depending upon the type of redox reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/40\">",
"     40",
"    </a>",
"    ]. Interaction between H2O2 and porphyrins in the presence of transition metals may contribute to the toxic effects of porphyrins observed in the absence of UV light (ie, dark effect).",
"   </p>",
"   <p>",
"    Secondary splenomegaly, developing in response to the increased removal of damaged red cells from the circulation, may contribute to the anemia, and may also result in leukopenia and thrombocytopenia (ie, hypersplenism). The latter is sometimes associated with significant bleeding and splenectomy may be beneficial in such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H29#H29\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Splenomegaly'",
"    </a>",
"    .) Anemia due to hemolysis can be severe, especially if the bone marrow is unable to fully compensate; as a result, some severely affected patients are transfusion dependent. Splenectomy may reduce the need for transfusions, although signs of ineffective erythropoiesis, including the formation of pigmented gallstones, may continue because of the dark effect of porphyrins (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/40,43\">",
"     40,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cutaneous changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of CEP, severe cutaneous photosensitivity usually begins in early infancy and is manifested by increased friability and blistering of the epidermis on the hands and face and other sun-exposed areas. Bullae and vesicles contain serous fluid and are prone to rupture and infection. The skin may be thickened, with areas of hypo- and hyperpigmentation. Hypertrichosis of the face and extremities is often prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/44\">",
"     44",
"    </a>",
"    ]. Sunlight, other sources of ultraviolet light, and minor skin trauma increase the severity of the cutaneous manifestations. Recurrent vesicles and secondary infection can lead to cutaneous scarring and deformities, as well as loss of finger nails and digits and severe damage to the eyelids, nose, and ears. Corneal scarring can lead to blindness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pink or reddish-brown staining of diapers due to markedly increased urinary excretion of porphyrins may be the first clue to the presence of this disorder.",
"   </p>",
"   <p>",
"    Porphyrins deposited in the teeth produce a reddish brown color in natural light, termed erythrodontia. The teeth may fluoresce on exposure to long wavelength ultraviolet light (",
"    <a class=\"graphic graphic_picture graphicRef68339 \" href=\"UTD.htm?15/23/15743\">",
"     picture 1",
"    </a>",
"    ). Porphyrin deposition in bone also occurs, and bone loss due to demineralization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/45\">",
"     45",
"    </a>",
"    ] or expansion of the hyperplastic bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] has been described. Later or adult-onset patients have milder clinical symptoms and often exhibit only the skin manifestations of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/2,48-50\">",
"     2,48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CEP is distinguishable from hepatoerythropoietic porphyria (HEP), a porphyria with clinical symptoms very similar to CEP but due to homozygous deficiency of UROD, by the absence of high levels of isocoproporphyrin in feces and urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of CEP is readily explained by markedly deficient UROS activity. This enzyme deficiency leads to accumulation of the substrate hydroxymethylbilane (HMB), which is converted nonenzymatically to uroporphyrinogen I (URO I). Although URO I can undergo decarboxylation via uroporphyrinogen decarboxylase (UROD) to form hepta-, hexa- and penta-carboxyl porphyrinogen I and finally coproporphyrinogen I (COPRO I), further metabolism cannot proceed because the next enzyme in the pathway, coproporphyrinogen oxidase, is stereospecific for the III isomer.",
"   </p>",
"   <p>",
"    Therefore, the isomer I porphyrins URO I and COPRO I are non-physiologic, in that they cannot be metabolized to heme, and are pathogenic compounds when they accumulate in large amounts and are auto-oxidized to the corresponding porphyrins. However, UROS activity is not totally deficient, even in severely affected homozygotes, since sufficient activity must be present in order to synthesize some uroporphyrinogen III and heme, the latter being essential for life.",
"   </p>",
"   <p>",
"    The large amounts of isomer I porphyrinogens that accumulate in bone marrow erythroid precursors (especially normoblasts and reticulocytes) and erythrocytes undergo autooxidation to the corresponding porphyrins, causing ineffective erythropoiesis and hemolysis. They are also deposited in tissues and bones, cause cutaneous photosensitivity, and are excreted in large amounts in urine and feces.",
"   </p>",
"   <p>",
"    Photosensitivity occurs because these porphyrins are photocatalytic compounds. Exposure of the skin to sunlight and other sources of long wave ultraviolet light results in blistering and vesicle formation and increased friability of the skin. Hemolysis is almost always present, but may not be accompanied by anemia if erythroid hyperplasia is sufficient to compensate for the increased rate of erythrocyte destruction. This degree of compensation may vary over time, such that, as an example, anemia may be exacerbated during episodes of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H23#H23\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Atypical presentations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     BIOCHEMICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary porphyrin excretion is markedly increased (up to 50 to 100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    normal range: less than 0.2 mg [0.3 micromol] per 24 hours) and consists mostly of uroporphyrin, hepta-carboxyl porphyrin, and coproporphyrin, with lesser increases in hexa- and penta-carboxyl porphyrins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/3\">",
"     3",
"    </a>",
"    ]. Although the absolute excretion of type III isomers may be increased, the predominant increase is in type I isomers, which may represent &gt;95 percent of the excreted porphyrins. In contrast, in normals and in the other porphyrias, type I isomers of uro- and coproporphyrin represent less than 5 percent of total urinary porphyrins.",
"   </p>",
"   <p>",
"    Urinary ALA and PBG excretion are not increased. Fecal porphyrins are markedly increased with a predominance of coproporphyrin I. Fecal isocoproporphyrins are not increased [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating erythrocytes in most reported cases of CEP have contained large amounts of uroporphyrin I, and lesser but still excessive amounts of coproporphyrin I. Red cell protoporphyrin may also be increased, and in some reported cases was the predominant porphyrin in erythrocytes, as in the bovine form of this disease. However, other porphyrias, such as hepatoerythropoietic porphyria (HEP) and erythropoietic protoporphyria (EPP), need to be considered if protoporphyrin is the predominant erythrocyte porphyrin.",
"   </p>",
"   <p>",
"    Excess plasma porphyrins, which probably originate from the bone marrow and circulating red cells, are mostly uroporphyrin and coproporphyrin. The bone marrow contains much larger amounts of porphyrins than other tissues in this disease, and these consist mostly of uroporphyrin and coproporphyrin. These porphyrins are also found in spleen and to a lesser extent in liver [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/39,52-56\">",
"     39,52-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erythrocyte porphobilinogen deaminase is increased in this disease and is attributable to increased erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/57\">",
"     57",
"    </a>",
"    ], as in other disorders associated with hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/58\">",
"     58",
"    </a>",
"    ]. Studies of nine Indian patients with CEP indicated a close relationship between the degree of porphyrin excess and the severity of disease expression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CEP should be suspected when severe photosensitivity begins in infancy or childhood, and porphyrins are markedly increased in both erythrocytes and urine. Pink to dark reddish urine or staining of the diaper noted shortly after birth may be the first clue to the diagnosis. In some cases the disease is less severe and presents in adult life with a hemolytic anemia or skin lesions suggestive of PCT. Full characterization of porphyrin patterns by a research laboratory to confirm a deficiency of uroporphyrinogen III cosynthase and to determine the nature of the underlying mutation is indicated to confirm a diagnosis of CEP (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Biochemical findings'",
"    </a>",
"    above). Some patients reported to have had CEP may have had PCT or HEP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/39,52\">",
"     39,52",
"    </a>",
"    ]; with modern diagnostic testing and molecular methods, these diseases are now readily differentiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prenatal and perinatal testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;CEP can cause nonimmune hydrops or hemolytic anemia in utero. The diagnosis can be established by measuring total porphyrins in amniotic fluid or cord blood plasma. Diagnosis of CEP in utero can avoid the harmful photosensitizing effects of photodynamic therapy for neonatal hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/51\">",
"     51",
"    </a>",
"    ]. If heterozygous parents have had a child with this disease, the disease can be detected in utero in future pregnancies by one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Red-brown discoloration and increased porphyrins (especially uroporphyrin I) in amniotic fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Measurement of UROS activity in cultured amniotic fluid cells [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Direct detection of UROS gene mutations in cultured amniotic cells [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of CEP includes the other porphyrias with cutaneous symptoms, such as hepatoerythropoietic porphyria (HEP), porphyria cutanea tarda (PCT), variegate porphyria (VP), hereditary coproporphyria (HCP), and erythropoietic protoporphyria (EPP).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HEP is clinically similar to CEP but is distinguishable by the predominance of protoporphyrin (complexed with zinc) in red cells and high levels of isocoproporphyrin in feces and urine.",
"     </li>",
"     <li>",
"      Homozygous forms of other porphyrias such as VP and HCP may also be characterized by photosensitivity in childhood and increased erythrocyte zinc protoporphyrin. In contrast to CEP, increased urinary concentrations of ALA and PBG are found during acute attacks in both VP and HCP. VP may be further differentiated by the presence of increased protoporphyrin in plasma and stool, while HCP is characterized by increases in coproporphyrin in plasma, urine, and stool.",
"     </li>",
"     <li>",
"      EPP is readily distinguished by a predominance of free protoporphyrin in erythrocytes and normal urinary porphyrins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of CEP involves three main components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protection from sunlight and UV exposure",
"     </li>",
"     <li>",
"      Meticulous skin care",
"     </li>",
"     <li>",
"      Red cell transfusions and other hematologic supportive care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Skin care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protection of the skin from sunlight and minor trauma is essential in most cases of congenital erythropoietic porphyria. Sunscreen lotions and b-carotene are sometimes beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/63\">",
"     63",
"    </a>",
"    ]. Bacterial infections that complicate cutaneous blisters require timely treatment in an effort to prevent scarring and mutilation. Severe infections such as cellulitis and bacteremia may require intravenous antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Red cell transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequent blood transfusions are sometimes essential. Repeated red cell transfusions can suppress erythropoiesis, thereby decreasing overall porphyrin production, and resulting in reduced porphyrin levels, with a consequent reduction in photosensitivity and hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/45\">",
"     45",
"    </a>",
"    ]. Such therapy is most likely to be successful if the hematocrit is maintained at levels above 32 percent and an iron chelator is administered to reduce the resulting iron overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapeutic interventions that may be tried in CEP include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      to reduce bone marrow porphyrin synthesis may be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Splenectomy may substantially reduce transfusion requirements in some patients with hypersplenism and excessive trapping and destruction of circulating red cells [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral charcoal may increase fecal loss of porphyrins [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/65\">",
"       65",
"      </a>",
"      ] and be useful for patients who are not transfusion-dependent and have milder disease. It is less successful in more severe cases [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/66\">",
"       66",
"      </a>",
"      ], and was associated with an apparent exacerbation in one case [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heme therapy, which is effective for treatment of the acute hepatic porphyrias, may be somewhat effective in CEP [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/49,68\">",
"       49,68",
"      </a>",
"      ], but has not been extensively studied. It seems unlikely to be able to provide long term benefit.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       Chloroquine",
"      </a>",
"      has not been beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/69-71\">",
"       69-71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) has been attempted and may become more useful in the future, as this is the only known curative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/72\">",
"     72",
"    </a>",
"    ]. To date eight patients have been cured by this modality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/4,19,72-77\">",
"     4,19,72-77",
"    </a>",
"    ], resulting in marked reduction of the photosensitivity and porphyrin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/19,72-75,77\">",
"     19,72-75,77",
"    </a>",
"    ]. Unfortunately, the first patient died of intercurrent cytomegalovirus infection, emphasizing the morbidity and mortality associated with this approach, even with HLA identical donors.",
"   </p>",
"   <p>",
"    Two children with CEP who underwent matched unrelated donor HCT developed complete donor chimerism along with correction of the enzymatic deficiency; they remain disease-free for 3 and 2 years post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A successful pregnancy has been reported in a patient with CEP and a moderate clinical phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of bone marrow transplantation in alleviating the severe manifestations of this disease provides the rationale for hematopoietic stem cell gene therapy. Because stable transduction of the patient's own stem cells with vectors containing the UROS cDNA would abrogate the need for HLA identical donors and the risk of rejection, efforts are underway to develop retroviral-mediated transduction of hematopoietic stem cells for treatment of patients with CEP.",
"   </p>",
"   <p>",
"    UROS cDNA has been subcloned into various retroviral vectors which have been used to transduce a variety of cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/79-83\">",
"     79-83",
"    </a>",
"    ]. Transduction of fibroblasts and lymphoblasts from patients with CEP resulted in significant levels of enzyme expression, ranging from 2 to 100-fold greater than the endogenous activity in CEP fibroblasts and up to 3-fold greater than that in normal lymphoblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/79,80,83\">",
"     79,80,83",
"    </a>",
"    ]. In addition, transduction of hematopoietic progenitor cells and early erythroid cells has been achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/81-84\">",
"     81-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retroviral transduction of this cell population with the therapeutic human UROS gene resulted in both enzymatic and metabolic correction of CD34+-derived cells, as demonstrated by the increase in UROS activity and by a 53 percent decrease in porphyrin accumulation. &nbsp;A 10 to 24 percent gene transfer efficiency was achieved in the most primitive cells, and gene expression remained stable during in vitro erythroid differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5801/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies indicate that in vitro gene transfer and persistent over-expression can indeed be effected in hematopoietic cells. However, the in vivo efficacy of individual retroviral vector constructs may not be predictable from these in vitro experiments and animal studies are needed. Such in vivo experiments could determine if transduction of hematopoietic stem cells can be efficient enough to minimize the proportion of non-transduced progenitors capable of producing toxic quantities of porphyrins in their descendants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13927988\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital erythropoietic porphyria (CEP, G&uuml;nther disease, erythropoietic porphyria) is a rare autosomal recessive inborn error of heme biosynthesis resulting from a markedly deficient activity of uroporphyrinogen III synthase.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pathogenesis",
"      </strong>",
"      &mdash; Uroporphyrinogen III synthase (UROS, uroporphyrinogen III cosynthase), catalyzes the conversion of the linear tetrapyrrole, hydroxymethylbilane (HMB), to the cyclic tetrapyrrole uroporphyrinogen III (URO III), the physiologic isomer which ultimately leads to the formation of heme (",
"      <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Enzymology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Clinical findings",
"      </strong>",
"      &mdash; Clinical severity of CEP is highly variable, ranging from non-immune hydrops fetalis due to severe hemolytic anemia in utero to milder, later-onset forms, which may have only cutaneous lesions in adult life. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mild to severe hemolysis is a feature of CEP and is accompanied by anisocytosis, poikilocytosis, polychromasia, basophilic stippling, reticulocytosis, increased circulating nucleated red cells, and absence of haptoglobin",
"     </li>",
"     <li>",
"      Severe cutaneous photosensitivity usually begins in early infancy and is manifested by increased friability and blistering of the epidermis on the hands and face and other sun-exposed areas.",
"     </li>",
"     <li>",
"      Pink or reddish-brown staining of diapers may be the first clue to the presence of this disorder. Porphyrins deposited in the teeth produce a reddish brown color in natural light, termed erythrodontia. The teeth may fluoresce on exposure to long wavelength ultraviolet light (",
"      <a class=\"graphic graphic_picture graphicRef68339 \" href=\"UTD.htm?15/23/15743\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diagnosis",
"      </strong>",
"      &mdash; Urinary porphyrin excretion is markedly increased and consists mostly of uroporphyrin, hepta-carboxyl porphyrin, and coproporphyrin. The predominant increase is in type I isomers, which may represent &gt;95 percent of the excreted porphyrins. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Biochemical findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Management",
"      </strong>",
"      &mdash; Management of CEP includes protection from sunlight and UV exposure, meticulous skin care, red cell transfusions for severe anemia, and supportive care (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      , splenectomy, oral charcoal). Hematopoietic cell transplantation is the only curative option. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/1\">",
"      Romeo G, Levin EY. Uroporphyrinogen 3 cosynthetase in human congenital erythropoietic porphyria. Proc Natl Acad Sci U S A 1969; 63:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/2\">",
"      Deybach JC, de Verneuil H, Phung N, et al. Congenital erythropoietic porphyria (G&uuml;nther's disease): enzymatic studies on two cases of late onset. J Lab Clin Med 1981; 97:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/3\">",
"      Fritsch C, Bolsen K, Ruzicka T, Goerz G. Congenital erythropoietic porphyria. J Am Acad Dermatol 1997; 36:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/4\">",
"      Desnick RJ, Astrin KH. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol 2002; 117:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/5\">",
"      BOGORAD L. The enzymatic synthesis of porphyrins from porphobilinogen. II. Uroporphyrin III. J Biol Chem 1958; 233:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/6\">",
"      Tsai SF, Bishop DF, Desnick RJ. Purification and properties of uroporphyrinogen III synthase from human erythrocytes. J Biol Chem 1987; 262:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/7\">",
"      Stevens E, Frydman RB, Frydman B. Separation of porphobilinogen deaminase and uroporphyrinogen 3 cosynthetase from human erythrocytes. Biochim Biophys Acta 1968; 158:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/8\">",
"      Tsai SF, Bishop DF, Desnick RJ. Coupled-enzyme and direct assays for uroporphyrinogen III synthase activity in human erythrocytes and cultured lymphoblasts. Enzymatic diagnosis of heterozygotes and homozygotes with congenital erythropoietic porphyria. Anal Biochem 1987; 166:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/9\">",
"      Shoolingin-Jordan PM, Leadbeater R. Coupled assay for uroporphyrinogen III synthase. Methods Enzymol 1997; 281:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/10\">",
"      Tsai SF, Bishop DF, Desnick RJ. Human uroporphyrinogen III synthase: molecular cloning, nucleotide sequence, and expression of a full-length cDNA. Proc Natl Acad Sci U S A 1988; 85:7049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/11\">",
"      Astrin KH, Warner CA, Yoo HW, et al. Regional assignment of the human uroporphyrinogen III synthase (UROS) gene to chromosome 10q25.2----q26.3. Hum Genet 1991; 87:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/12\">",
"      Bensidhoum M, Ged CM, Poirier C, et al. The cDNA sequence of mouse uroporphyrinogen III synthase and assignment to mouse chromosome 7. Mamm Genome 1994; 5:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/13\">",
"      Xu W, Kozak CA, Desnick RJ. Uroporphyrinogen-III synthase: molecular cloning, nucleotide sequence, expression of a mouse full-length cDNA, and its localization on mouse chromosome 7. Genomics 1995; 26:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/14\">",
"      Xu W, Astrin KH, Desnick RJ. Molecular basis of congenital erythropoietic porphyria: mutations in the human uroporphyrinogen III synthase gene. Hum Mutat 1996; 7:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/15\">",
"      Fontanellas A, Bensidhoum M, Enriquez de Salamanca R, et al. A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Eur J Hum Genet 1996; 4:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/16\">",
"      Desnick RJ, Glass IA, Xu W, et al. Molecular genetics of congenital erythropoietic porphyria. Semin Liver Dis 1998; 18:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/17\">",
"      Moruno Tirado A, Herrera Saval A, Martinez Montero E, et al. Congenital erythropoietic porphyria, description of a new mutation in two brothers. Eur J Pediatr 1997; 156:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/18\">",
"      Takamura N, Hombrados I, Tanigawa K, et al. Novel point mutation in the uroporphyrinogen III synthase gene causes congenital erythropoietic porphyria of a Japanese family. Am J Med Genet 1997; 70:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/19\">",
"      Tezcan I, Xu W, Gurgey A, et al. Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation. Blood 1998; 92:4053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/20\">",
"      Deybach JC, de Verneuil H, Boulechfar S, et al. Point mutations in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria (G&uuml;nther's disease). Blood 1990; 75:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/21\">",
"      Boulechfar S, Da Silva V, Deybach JC, et al. Heterogeneity of mutations in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Hum Genet 1992; 88:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/22\">",
"      de Verneuil H, Deybach JC, Grandchamp B, et al. Coexistence of two point mutations in the uroporphyrinogen III synthase gene in one case of CEP. Blood 1989; 74:105A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/23\">",
"      Bensidhoum M, Ged C, Hombrados I, et al. Identification of two new mutations in congenital erythropoietic porphyria. Eur J Hum Genet 1995; 3:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/24\">",
"      Tanigawa K, Bensidhoum M, Takamura N, et al. A novel point mutation in congenital erythropoietic porphyria in two members of Japanese family. Hum Genet 1996; 97:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/25\">",
"      Barker D, Schafer M, White R. Restriction sites containing CpG show a higher frequency of polymorphism in human DNA. Cell 1984; 36:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/26\">",
"      Cooper DN, Krawczak M. The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions. Hum Genet 1990; 85:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/27\">",
"      Solis C, Aizencang GI, Astrin KH, et al. Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria. J Clin Invest 2001; 107:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/28\">",
"      Phillips JD, Steensma DP, Pulsipher MA, et al. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood 2007; 109:2618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/29\">",
"      Warner CA, Yoo HW, Roberts AG, Desnick RJ. Congenital erythropoietic porphyria: identification and expression of exonic mutations in the uroporphyrinogen III synthase gene. J Clin Invest 1992; 89:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/30\">",
"      Xu W, Warner CA, Desnick RJ. Congenital erythropoietic porphyria: identification and expression of 10 mutations in the uroporphyrinogen III synthase gene. J Clin Invest 1995; 95:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/31\">",
"      Shady AA, Colby BR, Cunha LF, et al. Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene. Br J Haematol 2002; 117:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/32\">",
"      Warner CA, Poh-Fitzpatrick MB, Zaider EF, et al. Congenital erythropoietic porphyria. A mild variant with low uroporphyrin I levels due to a missense mutation (A66V) encoding residual uroporphyrinogen III synthase activity. Arch Dermatol 1992; 128:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/33\">",
"      Ged C, M&eacute;garban&eacute; H, Chouery E, et al. Congenital erythropoietic porphyria: report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling. J Invest Dermatol 2004; 123:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/34\">",
"      To-Figueras J, Ducamp S, Clayton J, et al. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. Blood 2011; 118:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/35\">",
"      Ged C, Mendez M, Robert E, et al. A knock-in mouse model of congenital erythropoietic porphyria. Genomics 2006; 87:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/36\">",
"      Bishop DF, Johansson A, Phelps R, et al. Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions. Am J Hum Genet 2006; 78:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/37\">",
"      Kontos AP, Ozog D, Bichakjian C, Lim HW. Congenital erythropoietic porphyria associated with myelodysplasia presenting in a 72-year-old man: report of a case and review of the literature. Br J Dermatol 2003; 148:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/38\">",
"      Cernik C, Haller N, Mostow EN. Adult-onset erythropoietic porphyria in the setting of MDS. Arch Dermatol 2009; 145:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/39\">",
"      SCHMID R, SCHWARTZ S, SUNDBERG RD. Erythropoietic (congenital) porphyria: A rare abnormality of the normoblasts. Blood 1955; 10:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/40\">",
"      Koningsberger JC, Van Asbeck BS, Van Hattum J, et al. The effect of porphyrins on cellular redox systems: a study on the dark effect of porphyrins on phagocytes. Eur J Clin Invest 1993; 23:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/41\">",
"      Pain RW, Welch FW, Woodroffe AJ, et al. Erythropoietic uroporphyria of Gunther first presenting at 58 years with positive family studies. Br Med J 1975; 3:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/42\">",
"      Weston MJ, Nicholson DC, Lim CK, et al. Congenital erythropoietic uroporphyria (G&uuml;nther's disease) presenting in a middle aged man. Int J Biochem 1978; 9:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/43\">",
"      Feurle GE, Ho AD, Wosiewitz U, Encke A. [Cholelithiasis in a previously not described case of congenital erythropoietic porphyria (author's transl)]. Dtsch Med Wochenschr 1980; 105:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/44\">",
"      Poh-Fitzpatrick MB. The erythropoietic porphyrias. Dermatol Clin 1986; 4:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/45\">",
"      Piomelli S, Poh-Fitzpatrick MB, Seaman C, et al. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. N Engl J Med 1986; 314:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/46\">",
"      Laorr A, Greenspan A. Severe osteopenia in congenital erythropoietic porphyria. Can Assoc Radiol J 1994; 45:307.",
"     </a>",
"    </li>",
"    <li>",
"     Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: Metabolic and Molecular Bases of Inherited Disease, 7th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 1995. Vol 2, p.2103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/48\">",
"      Kramer S, Viljoen E, Meyer AM, Metz J. The anaemia of erythropoietic prophyria with the description of the disease in an elderly patient. Br J Haematol 1965; 11:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/49\">",
"      Rank JM, Straka JG, Weimer MK, et al. Hematin therapy in late onset congenital erythropoietic porphyria. Br J Haematol 1990; 75:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/50\">",
"      Murphy A, Gibson G, Elder GH, et al. Adult-onset congenital erythropoietic porphyria (G&uuml;nther's disease) presenting with thrombocytopenia. J R Soc Med 1995; 88:357P.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/51\">",
"      Verstraeten L, Van Regemorter N, Pardou A, et al. Biochemical diagnosis of a fatal case of G&uuml;nther's disease in a newborn with hydrops foetalis. Eur J Clin Chem Clin Biochem 1993; 31:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/52\">",
"      Schmid R, Schwartz S, Watson CJ. Porphyrin content in bone marrow and liver in the various forms of porphyria. Arch Intern Med 1954; 93:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/53\">",
"      ALDRICH RA, HAWKINSON V, GRINSTEIN M, WATSON CJ. Photosensitive or congenital porphyria with hemolytic anemia. I. Clinical and fundamental studies before and after splenectomy. Blood 1951; 6:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/54\">",
"      WATSON CJ, PERMAN V, SPURRELL FA, et al. Some studies of the comparative biology of human and bovine porphyria erythropoietica. Trans Assoc Am Physicians 1958; 71:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/55\">",
"      Heilmeyer, VL, Clotten, R, Kerp, L, et al. Porphyria erythropoietica congenita Gunther. Dtsch Med Wochenschr 1963; 51:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/56\">",
"      Schwartz S, O'Connor N, Stephenson BD, et al. Turnover of erythrocyte protoporphyrin, with special reference to bovine porphyria and iron deficiency anemia. Ann Clin Res 1976; 8 Suppl 17:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/57\">",
"      Romeo G, Glenn BL, Levin EY. Uroporphyrinogen 3 cosynthetase in asymptomatic carriers of congenital erythpoietic porphyria. Biochem Genet 1970; 4:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/58\">",
"      Anderson KE, Sassa S, Peterson CM, Kappas A. Increased erythrocyte uroporphyrinogen-l-synthetase, delta-aminolevulinic acid dehydratase and protoporphyrin in hemolytic anemias. Am J Med 1977; 63:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/59\">",
"      Freesemann AG, Bhutani LK, Jacob K, Doss MO. Interdependence between degree of porphyrin excess and disease severity in congenital erythropoietic porphyria (G&uuml;nther's disease). Arch Dermatol Res 1997; 289:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/60\">",
"      Kaiser IH. Brown amiotic fluid in congenital erythropoietic porphyria. Obstet Gynecol 1980; 56:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/61\">",
"      Deybach JC, Grandchamp B, Grelier M, et al. Prenatal exclusion of congenital erythropoietic porphyria (G&uuml;nther's disease) in a fetus at risk. Hum Genet 1980; 53:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/62\">",
"      Ged C, Moreau-Gaudry F, Taine L, et al. Prenatal diagnosis in congenital erythropoietic porphyria by metabolic measurement and DNA mutation analysis. Prenat Diagn 1996; 16:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/63\">",
"      Mathews-Roth MM, Pathak MA, Fitzpatrick TB, et al. Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. Arch Dermatol 1977; 113:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/64\">",
"      Guarini L, Piomelli S, Poh-Fitzpatrick MB. Hydroxyurea in congenital erythropoietic porphyria. N Engl J Med 1994; 330:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/65\">",
"      Tishler PV, Winston SH. Rapid improvement in the chemical pathology of congenital erythropoietic porphyria with treatment with superactivated charcoal. Methods Find Exp Clin Pharmacol 1990; 12:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/66\">",
"      Minder EI, Schneider-Yin X, M&ouml;ll F. Lack of effect of oral charcoal in congenital erythropoietic porphyria. N Engl J Med 1994; 330:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/67\">",
"      Hift RJ, Meissner PN, Kirsch RE. The effect of oral activated charcoal on the course of congenital erythropoietic porphyria. Br J Dermatol 1993; 129:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/68\">",
"      Watson CJ, Bossenmaier I, Cardinal R, Petryka ZJ. Repression by hematin of porphyrin biosynthesis in erythrocyte precursors in congenital erythropoietic porphyria. Proc Natl Acad Sci U S A 1974; 71:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/69\">",
"      VARADI S. [Haematological aspects in a case of erythropoietic porphyria]. Br J Haematol 1958; 4:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/70\">",
"      Kaufman BM, Vickers HR, Rayne J, Ryan TJ. Congenital erythropoietic porphyria. Report of a case. Br J Dermatol 1967; 79:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/71\">",
"      Moore MR, Thompson GG, Goldberg A, et al. The biosynthesis of haem in congenital (erythropoietic) porphyria. Int J Biochem 1978; 9:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/72\">",
"      Kauffman L, Evans DI, Stevens RF, Weinkove C. Bone-marrow transplantation for congenital erythropoietic porphyria. Lancet 1991; 337:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/73\">",
"      Thomas C, Ged C, Nordmann Y, et al. Correction of congenital erythropoietic porphyria by bone marrow transplantation. J Pediatr 1996; 129:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/74\">",
"      Zix-Kieffer I, Langer B, Eyer D, et al. Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease). Bone Marrow Transplant 1996; 18:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/75\">",
"      Shaw PH, Mancini AJ, McConnell JP, et al. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant 2001; 27:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/76\">",
"      Harada FA, Shwayder TA, Desnick RJ, Lim HW. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol 2001; 45:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/77\">",
"      Dupuis-Girod S, Akkari V, Ged C, et al. Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (G&uuml;nther disease). Eur J Pediatr 2005; 164:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/78\">",
"      Hallai N, Anstey A, Mendelsohn S, et al. Pregnancy in a patient with congenital erythropoietic porphyria. N Engl J Med 2007; 357:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/79\">",
"      Moreau-Gaudry F, Mazurier F, Bensidhoum M, et al. Metabolic correction of congenital erythropoietic porphyria by retrovirus-mediated gene transfer into Epstein-Barr virus-transformed B-cell lines. Blood 1995; 85:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/80\">",
"      Moreau-Gaudry F, Ged C, Barbot C, et al. Correction of the enzyme defect in cultured congenital erythropoietic porphyria disease cells by retrovirus-mediated gene transfer. Hum Gene Ther 1995; 6:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/81\">",
"      Moreau-Gaudry F, Barbot C, Mazurier F, et al. Correction of the enzyme deficit of bone marrow cells in congenital erythropoietic porphyria by retroviral gene transfer. Hematol Cell Ther 1996; 38:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/82\">",
"      Mazurier F, Moreau-Gaudry F, Salesse S, et al. Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria. J Inherit Metab Dis 1997; 20:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/83\">",
"      Kauppinen R, Glass IA, Aizencang G, et al. Congenital erythropoietic porphyria: prolonged high-level expression and correction of the heme biosynthetic defect by retroviral-mediated gene transfer into porphyric and erythroid cells. Mol Genet Metab 1998; 65:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5801/abstract/84\">",
"      Mazurier F, G&eacute;ronimi F, Lamrissi-Garcia I, et al. Correction of deficient CD34+ cells from peripheral blood after mobilization in a patient with congenital erythropoietic porphyria. Mol Ther 2001; 3:411.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7102 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5801=[""].join("\n");
var outline_f5_42_5801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13927988\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENZYMOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Enzyme properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      The UROS gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mutations in CEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genotype phenotype correlations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mouse model of CEP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hematologic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cutaneous changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      BIOCHEMICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prenatal and perinatal testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Skin care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Red cell transfusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13927988\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7102|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25077\" title=\"figure 1\">",
"      Heme synthesis and porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/50/35617\" title=\"figure 2\">",
"      Heme biosynthetic pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7102|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/23/15743\" title=\"picture 1\">",
"      Erythrodontia in CEP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_42_5802="Cardiac syndrome X: Angina pectoris with normal coronary arteries";
var content_f5_42_5802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/42/5802/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5802/contributors\">",
"     Imran Chaudhary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/42/5802/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5802/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/42/5802/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/42/5802/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/42/5802/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac syndrome X is a clinical entity that needs to be distinguished from angina pectoris due to typical obstructive coronary heart disease. It has three characteristic features, each of which can be seen in other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angina or angina-like chest pain with exertion",
"     </li>",
"     <li>",
"      ST segment depression on treadmill exercise testing",
"     </li>",
"     <li>",
"      Normal coronary arteriography, with no spontaneous or inducible epicardial coronary artery spasm on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"       ergonovine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      provocation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical characteristics, diagnosis, and treatment of cardiac syndrome X will be reviewed here. Two main and not mutually exclusive pathogenetic mechanisms have been proposed: myocardial ischemia; and heightened sensitivity to intracardiac pain or the so-called \"sensitive heart\" syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Noncardiac causes of chest pain must also be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac syndrome X should not be confused with the metabolic syndrome, which is also called syndrome X but refers to the constellation of insulin resistance, obesity, hypertension, diabetes, and dyslipidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac syndrome X is primarily applied to patients with suspected stable ischemic chest pain. There are two other settings in which coronary ischemia occurs with normal or near-normal coronary arteries, which are not considered part of cardiac syndrome X. First, a minority of patients with an acute coronary syndrome have normal or near-normal coronary arteries. Second, some patients present with stress-induced cardiomyopathy, a disorder that is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a problem with the inclusion of patients with \"near-normal\" (ie, &lt;50 percent) stenosis under the category of cardiac syndrome X since, in many cases, dynamic changes (ie, coronary vasoconstriction) occurring at the site of such stenoses are responsible for epicardial flow limitations that lead to angina. It is generally required that patients with cardiac syndrome X have completely normal coronary arteriograms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with chest pain who are referred for coronary angiography, 15 to 20 percent have normal vessels or no vessel with &ge;50 percent stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The largest experience comes from the Coronary Artery Surgery Study (CASS) registry in which normal or near normal coronary angiograms were noted in 19 percent of 21,487 procedures performed at 15 sites [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a strong preponderance of women in patients with cardiac syndrome X, many of whom are perimenopausal or postmenopausal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. In a study of 886 patients referred for angiographic evaluation of chest pain, normal coronary arteries were found in 41 percent of the women compared to only 8 percent of the men (16 percent overall) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/7\">",
"     7",
"    </a>",
"    ]. Similar findings were noted in a series of 323 women (mean age 59) with suspected or possible ischemic chest pain: 37 percent had normal coronary arteries (less than 20 percent stenosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not included within the definition of cardiac syndrome X, normal coronary vessels or no vessel with &ge;50 to 60 percent stenosis has been reported in approximately 9 to 14 percent of patients with a non-ST elevation acute coronary syndrome (ACS, unstable angina or a non-ST elevation myocardial infarction) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]; approximately one-half of these patients had no detectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. A somewhat lower rate of no critical lesion (7.5 percent) has been noted in patients with an ST elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/17\">",
"     17",
"    </a>",
"    ]. The absence of critical coronary lesions is about 1.5 to 2.0 times as common in women compared to men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/13-15,17\">",
"     13-15,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RELATIONSHIP TO VARIANT ANGINA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible mechanisms for the absence of significant coronary disease in these patients include rapid clot lysis, coronary vasospasm (variant angina), cocaine use, inherited thrombophilia, and coronary microvascular disease (",
"    <a class=\"graphic graphic_table graphicRef74465 \" href=\"UTD.htm?20/15/20733\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. In favor of the last mechanism is the observation in a report from the TIMI IIIA trial that approximately one-third of these patients had abnormally slow angiographic filling (TIMI flow grade 2 or less) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link&amp;anchor=H10#H10\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\", section on 'Absence of significant coronary disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link\">",
"     \"Variant angina\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the name cardiac syndrome X implies, the exact basis for the signs and symptoms of this condition has not been elucidated. Some general statements can be made, however, regarding the clinical profile of these patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, cardiac syndrome X is much more common in women than men [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/7,9,10\">",
"       7,9,10",
"      </a>",
"      ]. Patients with this disorder are typically younger than those with angina due to coronary disease (mean age 49&plusmn;9 years in two series) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In approximately one-half of patients, the chest pain is similar to angina-like pain. Others have atypical chest pain, which may be severe and debilitating to a point where it affects daily activities [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/9\">",
"       9",
"      </a>",
"      ]. The pain may be precipitated by effort, but also occurs at rest [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/4,19\">",
"       4,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The duration of anginal-type chest pain is often",
"      <strong>",
"       prolonged",
"      </strong>",
"      . This was illustrated in a review of 99 patients with cardiac syndrome X: the average duration of chest pain was more than 10 minutes in 53 percent, and more than 30 minutes in 35 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/9\">",
"       9",
"      </a>",
"      ]. Many patients did not respond to sublingual nitrates.",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coronary microvascular dysfunction is present in 20 to 50 percent of women with chest pain and normal coronary arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/20-24\">",
"       20-24",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=see_link&amp;anchor=H5#H5\">",
"       \"Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis\", section on 'Endothelial cell dysfunction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There may be a strong association between cardiac syndrome X and psychiatric disorders such as panic anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rheumatologic disorders, such as fibromyalgia and costochondritis, and noncardiac causes of chest pain, such as esophageal dysfunction, have occasionally been reported in patients with cardiac syndrome X [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=see_link\">",
"       \"Chest pain of esophageal origin\"",
"      </a>",
"      .) Thus, a significant proportion of patients who are labeled with the diagnosis of cardiac syndrome X may not have a cardiac etiology for the chest discomfort.",
"     </li>",
"     <li>",
"      Occasional patients (5 of 153 in one report) have underlying systemic amyloidosis in which the chest pain may result from amyloid deposits in the intramyocardial coronary arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. The diagnosis of amyloidosis may not be made for several years after the onset of chest pain, usually due to the development of renal disease or heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until a specific diagnostic test is available, the diagnosis of cardiac syndrome X is one of exclusion. The possibility of cardiac syndrome X should be considered when a patient (often a postmenopausal or perimenopausal woman) describes effort-related anginal pain that lasts 10 minutes or longer after cessation of activity and that responds inconsistently to sublingual nitrates. However, in many patients, the response to sublingual nitrates is indistinguishable from that in patients with typical stable angina caused by obstructive coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence of ischemia has not been necessary for the diagnosis of cardiac syndrome X for at least two reasons: coronary microvascular dysfunction may cause anginal pain without detectable ischemia; and the techniques available for detecting the mild or patchy distribution of myocardial ischemia resulting from coronary microvascular disease have had limited sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/28\">",
"     28",
"    </a>",
"    ]. Although cardiovascular magnetic resonance imaging may overcome these limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/1\">",
"     1",
"    </a>",
"    ], ischemia may not be the primary mechanism in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient ECG changes (ST segment depression with anginal pain) in patients with cardiac syndrome X imply a cardiac origin of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/29\">",
"     29",
"    </a>",
"    ], but the absence of ECG changes does not exclude a cardiac etiology because of the low sensitivity of the ECG. ST-segment elevation that is the hallmark of variant (Prinzmetal's) angina is not a feature of cardiac syndrome X [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/28\">",
"     28",
"    </a>",
"    ]. Ambulatory ECG monitoring for 24 hours may be helpful for documenting ST segment changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pain suggestive of angina generally undergo treadmill exercise testing. The typical finding in cardiac syndrome X on the ECG is horizontal or downsloping ST segment depression during exercise, as seen in patients with obstructive coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=see_link\">",
"     \"Electrocardiographic changes during exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The coronary arteries in patients with cardiac syndrome X appear to have an abnormal response to vasomotor stimuli, such as adenosine, that may lead to reduced coronary blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise thallium-201 myocardial scintigraphy may demonstrate regional myocardial perfusion defects during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, some reports have demonstrated neither perfusion defects nor regional wall motion abnormalities after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    or transesophageal atrial pacing, despite the frequent provocation of chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/10,32\">",
"     10,32",
"    </a>",
"    ]. It is possible that ischemia is limited to the subendocardium, which could explain the absence of wall motion abnormalities as assessed by echocardiography (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Other tests'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocardial perfusion defects may be associated with endothelial dysfunction in both the coronary and systemic circulations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=see_link&amp;anchor=H5#H5\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis\", section on 'Endothelial cell dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise perfusion imaging also may show evidence of left ventricular systolic and diastolic dysfunction, which is consistent with ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/33\">",
"     33",
"    </a>",
"    ]. However, other reports found no decline in left ventricular function with stress in patients with cardiac syndrome X [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/10,32,34\">",
"     10,32,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac magnetic resonance (CMR) perfusion imaging is able to detect regional differences in myocardial blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/35\">",
"     35",
"    </a>",
"    ]. In a study of 18 cardiac syndrome X patients and 10 healthy controls, myocardial perfusion defects detected by gadolinium enhanced CMR at rest and at peak",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress were correlated to coronary flow response (CFR) to adenosine in left anterior descending (LAD) coronary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/36\">",
"     36",
"    </a>",
"    ]. CFR to adenosine in LAD was lower in cardiac syndrome X patients than in control subjects. The cardiac syndrome X patients with dobutamine stress induced myocardial perfusion defects in LAD territory on CMR had a lower CFR to adenosine compared to those without perfusion defects in LAD territory [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/36\">",
"     36",
"    </a>",
"    ]. Significant correlation was found between CFR to adenosine and dobutamine stress induced perfusion defect score on CMR in LAD territory [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/36\">",
"     36",
"    </a>",
"    ]. This study is evidence of coronary microcirculation dysfunction in patients with cardiac syndrome X.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal coronary angiogram is a necessary component of the diagnosis of cardiac syndrome X. Other tests can be performed at the time of angiography that may be of value:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"       Ergonovine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      provocation tests can test for epicardial coronary vasospasm, which establishes the diagnosis of variant angina. Intracoronary acetylcholine can also detect coronary endothelial dysfunction, which appears to identify patients with chest pain and normal coronary angiograms who are at increased risk for subsequent atherosclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link\">",
"       \"Variant angina\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Risk stratification'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Intravascular ultrasonography (IVUS) may detect intramural atheroma, which can be responsible for dynamic changes in caliber that lead to myocardial ischaemia in some patients labeled as cardiac syndrome X [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tissue level perfusion, as determined by the myocardial blush grade on coronary arteriography, was evaluated in a series of 55 patients with cardiac syndrome X and 44 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/24\">",
"       24",
"      </a>",
"      ]. An abnormal blush grade was significantly more common in patients with cardiac syndrome X (58 versus 20 percent in controls). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H4#H4\">",
"       \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'Myocardial tissue perfusion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests that have primarily been used in research settings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous administration of adenosine provokes chest pain in most patients with cardiac syndrome X in association with absence of the expected increase in subendocardial perfusion as detected by cardiac magnetic resonance imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/1\">",
"       1",
"      </a>",
"      ]. This observation suggests an important role for myocardial ischemia.",
"     </li>",
"     <li>",
"      Measurement of myocardial high-energy phosphates after hand-grip exercise, using nuclear magnetic resonance spectroscopy, has provided evidence of myocardial ischemia, perhaps due to microvascular disease (eg, coronary endothelial dysfunction), in a subset of patients with chest pain and no significant lesions on coronary angiography [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. The fact that this study was abnormal in only 20 percent of patients suggests that cardiac syndrome X is heterogeneous, which is consistent with the conflicting findings described above for perfusion defects, regional wall motion abnormalities, and changes in left ventricular function.",
"     </li>",
"     <li>",
"      During incremental pacing, the coronary sinus oxygen saturation in some reports decreased progressively, a change that is typically observed in patients with flow-limiting stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/40\">",
"       40",
"      </a>",
"      ]. However, this finding was not confirmed in a study in which a reduction in coronary sinus oxygen saturation was not seen in all patients and, when it did occur, was small and was less than that seen in patients with coronary artery disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/41\">",
"       41",
"      </a>",
"      ]. Furthermore, most patients with normal coronary arteries did not demonstrate metabolic evidence of myocardial ischemia, such as a fall in coronary sinus blood pH or a reduction in myocardial lactate extraction ratio.",
"     </li>",
"     <li>",
"      Nuclear exercise studies,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"        dipyridamole",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"        ergonovine",
"       </a>",
"      </span>",
"      testing, and pacing-induced tachycardia have all been used to demonstrate coronary microvascular alterations; however, they have a limited capacity for detecting either mild or patchy ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/28,40,42,43\">",
"       28,40,42,43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As discussed above, there is a higher prevalence of Cardiac Syndrome X in women. In addition gender differences exist in the clinical presentation of ischemic heart disease. It is probably due to these differences, that various diagnostic modalities used in evaluation of patients with ischemic heart disease perform differently in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2001 study evaluated methods to optimize symptom evaluation and diagnostic testing for ischemic heart disease in women and to explore the mechanisms for symptoms and myocardial ischemia in the absence of epicardial coronary artery stenoses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/44\">",
"     44",
"    </a>",
"    ]. Only 39% of women evaluated with coronary angiograms for classic anginal symptoms had significant epicardial CAD and classification of \"atypical\" angina missed up to 65% of women who actually had CAD. A relatively low sensitivity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography testing for significant multivessel disease in women with suspected myocardial ischemia was found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive technique for the diagnosis of cardiac syndrome X is not currently available. Many patients with chest pain and normal coronary angiograms have neither metabolic nor hemodynamic evidence of myocardial ischemia. Causes of nonischemic chest pain such as esophageal dysfunction, pulmonary hypertension, and mitral valve prolapse, should also be considered and pursued. With esophageal dysmotility, for example, the chest pain can be reproduced by infusion of hydrochloric acid into the esophagus (Bernstein test) or by intraesophageal balloon distention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=see_link\">",
"     \"Chest pain of esophageal origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of cardiac syndrome X is usually established by the demonstration of normal epicardial coronary arteries on coronary arteriography in a patient with a chest discomfort typical for angina pectoris who has a positive response to exercise testing. However, a positive exercise test or other evidence of ischemia is not necessarily present in cardiac syndrome X, and patients without such findings frequently do not undergo arteriography. In this setting, the diagnosis of cardiac syndrome X can be suspected but not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cardiac syndrome X with stable angina have a generally excellent prognosis, while those with acute coronary syndromes have an appreciable acute mortality although lower than that in patients with angiographic coronary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Stable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis is generally benign in patients with cardiac syndrome X who have stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/5,9,45-48\">",
"     5,9,45-48",
"    </a>",
"    ]. The largest experience comes from the CASS registry of over 4000 patients with normal or near normal coronary arteriograms and a left ventricular ejection fraction greater than 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/5\">",
"     5",
"    </a>",
"    ]. The seven-year survival rate was 96 percent in those with normal arteriograms and 92 percent in those with mild disease.",
"   </p>",
"   <p>",
"    Only a minority of patients show evidence of progressive disease on repeat arteriography. In a series of 138 patients with chest pain and normal or near normal (minimal luminal irregularities) coronary angiography at baseline, angiography was repeated in 24 during a five-year follow-up because of unstable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/47\">",
"     47",
"    </a>",
"    ]. Only two patients had progression to significant stenosis; both were men with coronary risk factors and both had minimal irregularities at baseline. Similar findings were noted in another report in which single vessel disease developed in only two of 17 patients as detected on a second arteriogram performed for persistent symptoms a mean of nine years after the initial examination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with cardiac syndrome X and stable angina are at increased cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/38\">",
"     38",
"    </a>",
"    ]. As an example, measurement of myocardial high-energy phosphates after hand-grip exercise, using nuclear magnetic resonance spectroscopy (MRS), has provided evidence of myocardial ischemia, perhaps due to microvascular disease, in approximately 20 percent of women with cardiac syndrome X [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic importance of this finding was illustrated in a study of women referred for coronary angiography for suspected myocardial ischemia who also underwent MRS hand-grip testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/21\">",
"     21",
"    </a>",
"    ]. At three years, the frequency of cardiovascular events (primarily hospitalization for unstable angina) was 13 percent in the 60 women with no obstructive CHD and normal MRS, 43 percent in the 14 women with no obstructive CHD and an abnormal MRS, and 48 percent in a reference population of 352 women with CHD.",
"   </p>",
"   <p>",
"    Stress testing may be another method to detect patients at increased risk. This was illustrated in a study of 457 patients, 359 with normal coronary arteriograms, and the remainder with less than 50 percent stenosis; all patients had normal left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/49\">",
"     49",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     Dipyridamole",
"    </a>",
"    stress echocardiography was abnormal in 43 patients (9 percent). At a median follow-up of 7.1 years, these patients had, compared to those with a normal stress test, significantly higher rates of overall mortality (18 versus 7 percent) and cardiac mortality (7.0 versus 2.7 percent). On multivariate analysis, independent risk factors for reduced survival were a higher wall motion score index at peak stress and mild to moderate changes on the initial arteriogram (as also noted above in the CASS registry [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/5\">",
"     5",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    The prognostic importance of coronary endothelial dysfunction, as assessed by focal coronary artery spasm after intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"     acetylcholine",
"    </a>",
"    , was evaluated in a study of 42 women (age range 38 to 66 years) who had angina, reversible myocardial perfusion defects on stress SPECT imaging, and normal coronary arteries on angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/37\">",
"     37",
"    </a>",
"    ]. The following findings were noted at follow-up of more than ten years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 20 patients with normal endothelial function (coronary vasodilation after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      ), all had complete resolution of chest pain after six to 36 months. At the end of follow-up both stress SPECT imaging and repeat angiography were normal.",
"     </li>",
"     <li>",
"      Among the 22 patients with coronary endothelial dysfunction, eight had complete resolution of symptoms, 13 had persistent episodes of angina, and there was one cardiac death. At the end of follow-up, all of the patients with persistent symptoms had developed mild angiographic coronary disease (mean 32 percent diameter stenosis), while the angiogram remained normal in the four asymptomatic patients who were tested.",
"     </li>",
"     <li>",
"      There were no significant differences in coronary risk factors between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Non-ST elevation ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome is not benign in patients with a non-ST elevation ACS, although it is much better than in those with a culprit coronary lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/13,14,50\">",
"     13,14,50",
"    </a>",
"    ]. This was best illustrated in the PURSUIT trial of 5767 patients with unstable angina or a non-ST elevation myocardial infarction: 6 percent had mild coronary disease (&gt;0 to &le;50 percent stenosis) and 6 percent had no disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/14\">",
"     14",
"    </a>",
"    ]. The patients with no or mild coronary disease had a much lower rate of death or nonfatal MI at 30 days than those with significant disease (2 and 6 versus 17 percent). A similar difference in short-term prognosis was noted in the TIMI IIIA trial (2 versus 18 percent rate of death or nonfatal MI) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Stress-induced cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncommon but increasingly reported cause of an acute, usually ST elevation coronary syndrome occurring in the absence of critical coronary artery disease is stress-induced cardiomyopathy, also called transient left ventricular apical ballooning, takotsubo cardiomyopathy, and broken heart syndrome. This disorder is typically precipitated by intense psychologic stress and primarily occurs in postmenopausal women. The characteristic finding of apical ballooning is seen on left ventriculography or echocardiography. Despite frequent hemodynamic compromise or even cardiogenic shock, almost all patients recover completely within one to four weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different therapeutic strategies have been proposed for the management of cardiac syndrome X depending upon the prevailing pathogenic mechanism, comorbidity, and clinical presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Among patients with stable angina, reassurance has been an integral aspect of management because of the presumption that most such patients have a benign prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/53\">",
"     53",
"    </a>",
"    ]. However, as noted above, some patients are at increased risk for the subsequent development of angiographic coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Risk stratification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with an acute coronary syndrome who have a coronary arteriogram that is either normal or does not show a culprit lesion have a 2 percent short-term mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Other than not being candidates for reperfusion or revascularization, these patients should be treated the same as those who have a culprit lesion, including aggressive risk factor reduction. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Acute coronary syndrome'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary goal of medical therapy is relief of pain, which persists in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/9,37,52\">",
"     9,37,52",
"    </a>",
"    ]. In one of the above reports, for example, symptoms were variable or unchanged in 64 percent, increased in 24 percent, and lessened in only 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/9\">",
"     9",
"    </a>",
"    ]. Furthermore, the rate of return to work was poor.",
"   </p>",
"   <p>",
"    Large randomized trials have not been performed to assess symptom control in cardiac syndrome X [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/38,52\">",
"     38,52",
"    </a>",
"    ]. Therapy is largely empiric and optimal therapy may vary with the mechanism of cardiac syndrome X [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although definitive controlled trials are not available, beta blockers seem to be most effective in reducing the frequency and severity of angina and in improving exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. The potential efficacy was illustrated in a randomized crossover trial in which ten patients with effort angina, ischemic-like ST segment changes with exercise, and totally normal coronary arteries on angiography were treated for four weeks with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or a nitrate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/54\">",
"     54",
"    </a>",
"    ]. Atenolol significantly reduced the number of anginal episodes (15 versus 24 episodes per four weeks at baseline) and improved quality-of-life measures, although benefit was only seen in six of the ten patients. Amlodipine also improved the quality-of-life but had no effect on the frequency of angina, while the nitrate had no effect on either parameter.",
"   </p>",
"   <p>",
"    Similar relative benefits were noted in a report of 16 patients in whom heightened sympathetic activity appeared to play an important role in the initiation of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/55\">",
"     55",
"    </a>",
"    ]. Compared to placebo, the number of ischemic episodes per day (defined as ST depression &ge;0.15 mV with continuous ECG monitoring) fell with 120 to 160 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    per day (0.7 versus 3.9) but not with 320 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=see_link&amp;anchor=H6#H6\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis\", section on 'Autonomic abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two studies cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] and other reports suggest that calcium channel blockers are not effective or less predictably effective in patients with cardiac syndrome X [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variable results have been described with nitrate therapy, ranging from no benefit with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/54\">",
"     54",
"    </a>",
"    ] to improvement with sublingual nitrates in about 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     ACE inhibitors and statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial small study suggested a potential benefit of therapy with an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/59\">",
"     59",
"    </a>",
"    ]. This was followed by a randomized trial in which 45 patients with cardiac syndrome X were assigned to treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    (10 mg daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (40 mg daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/60\">",
"     60",
"    </a>",
"    ]. After six months, patients treated with atorvastatin and ramipril had significant improvements in brachial artery flow-mediated vasodilation (a marker of endothelial function), exercise duration, and angina frequency compared to placebo.",
"   </p>",
"   <p>",
"    The mechanism of benefit of such therapy is not certain but may be a consequence of reduction in oxidative stress. During the study, measurements of superoxide dismutase (SOD) activity were made before and after six months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/60\">",
"     60",
"    </a>",
"    ]. Baseline SOD levels were elevated compared to healthy control subjects, suggesting an induced increase enzyme activity to counter elevated superoxide anion formation. After treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , but not placebo, SOD levels were significantly reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link&amp;anchor=H4#H4\">",
"     \"Endothelial dysfunction\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Imipramine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    , which has been used successfully in the management of chronic pain syndromes, may be effective in some patients with cardiac syndrome X. One study, for example, evaluated 60 patients with chest pain and normal coronary arteriograms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/61\">",
"     61",
"    </a>",
"    ]. Only 13 had ischemic changes with exercise on the ECG, while 22 had abnormal esophageal motility, and 38 had one or more psychiatric disorders. Almost all had their characteristic chest pain provoked by right ventricular electrical stimulation or intracoronary infusion of adenosine.",
"   </p>",
"   <p>",
"    The patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    (50 mg nightly),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    (0.1 mg BID), or placebo. A benefit was seen only with imipramine, which reduced the frequency of chest pain in patients with cardiac syndrome X by approximately 50 percent. Patients treated with imipramine also had a significant reduction in the prevalence of chest pain provoked by right ventricular electrical stimulation, but there was no change in esophageal sensitivity to balloon distension. The psychiatric profile during the course of treatment did not change and the benefit was seen in both men and women.",
"   </p>",
"   <p>",
"    However, side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    therapy often limit the overall benefit. This was illustrated in a prospective, randomized, double-blind, crossover trial of imipramine (50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and placebo in 18 women (median age 53 years; range 35 to 72) with chest pain and normal coronary angiograms who were suffering at least two anginal episodes per week [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/62\">",
"     62",
"    </a>",
"    ]. Despite conventional antianginal medications, imipramine improved chest pain, but 83 percent developed side effects and quality of life not significantly improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormone therapy may be beneficial in postmenopausal women. In a double-blind controlled trial of 25 such women, hormone therapy significantly reduced the frequency of anginal episodes (3.7 versus 7.3 episodes per 10 days with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/63\">",
"     63",
"    </a>",
"    ]. Exercise duration was not changed. Estrogen may act by improving endothelium-dependent coronary vasomotion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these benefits must be weighed against the overall effect of hormone therapy on cardiovascular outcomes. The Women's Health Initiative, mostly of primary prevention, and the HERS trials of secondary prevention showed that estrogen-progestin replacement had no cardioprotective effect and may have produced harm, increasing the risk of coronary disease, stroke, venous thromboembolism, and breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Physical training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with cardiac syndrome X have impaired exercise tolerance, despite normal skeletal muscle function, with signs of pain hypersensitivity during exercise. This may be related, in part, to physical deconditioning.",
"   </p>",
"   <p>",
"    The potential benefit of physical training was demonstrated in a trial of 26 patients who were randomly assigned to eight weeks of body-awareness training followed by eight weeks of exercise training, eight weeks of exercise training only, or no intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/65\">",
"     65",
"    </a>",
"    ]. Body-awareness training did not alter the pain response to exercise. However, compared to no intervention, exercise training improved exercise capacity by 34 percent and delayed the onset of pain during exercise by 100 percent, although the maximum pain was unchanged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Alpha blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of coronary microvascular constriction by an alpha-adrenergic blocker is theoretically attractive. However, most studies have shown no effect on exercise-induced angina [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/66,67\">",
"     66,67",
"    </a>",
"    ] and alpha-1 blockade does not affect myocardial blood flow at rest or after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or the development of chest pain and ischemic ECG changes after dipyridamole [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Aminophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine has been implicated in the pathogenesis of syndrome X, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    , which is an adenosine receptor antagonist, has been demonstrated to have a protective effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=see_link&amp;anchor=H5#H5\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis\", section on 'Endothelial cell dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     Aminophylline",
"    </a>",
"    may be of clinical benefit as well [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In a trial of oral aminophylline, the time to the development of chest pain on exercise testing was prolonged and the number of chest pain episodes over a three week interval were reduced, but the development of ST segment depression was not diminished [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Spinal cord stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord stimulation has been successful in the treatment of refractory angina due to coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=see_link&amp;anchor=H23#H23\">",
"     \"New therapies for angina pectoris\", section on 'Spinal cord stimulation'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Some patients with cardiac syndrome X have frequent episodes of severe chest pain that are refractory to maximal antianginal therapy. In a small, randomized crossover trial of ten such patients, spinal cord stimulation reduced the number, duration, and severity of spontaneous anginal episodes and prolonged the time to angina and to ST segment depression during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no \"set rules\" for the treatment of cardiac syndrome X, and therapy should be tailored to the individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with stable angina, we recommend initial therapy with sublingual nitrates as needed, risk factor reduction, and reassurance of the patient regarding his or her condition. If this is ineffective, the administration of a beta blocker is often beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. The likelihood of response appears to be less with a calcium channel blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/38,54,55\">",
"     38,54,55",
"    </a>",
"    ]. Short-acting calcium channel blockers should not be used because of safety concerns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     Imipramine",
"    </a>",
"    can be tried if the above medications are ineffective; it can also be used as an initial option in patients with significant functional overlay [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/61\">",
"     61",
"    </a>",
"    ]. However, side effects occur in most patients and often prevent an improvement in the quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A physical training program may improve exercise capacity and reduce the frequency of chest pain episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/42/5802/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454739\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac syndrome X is defined as angina-like chest pain with exertion, positive ECG response (ST segment depression) on treadmill exercise testing and normal coronary angiography with no spontaneous or inducible epicardial coronary artery spasm on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"       ergonovine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      provocation.",
"     </li>",
"     <li>",
"      There is a strong preponderance of women in patients with cardiac syndrome X and many of them are perimenopausal or post menopausal. These patients tend to be younger than those with angina due to obstructive coronary disease. A small proportion (7 to 14 percent) of patients with acute coronary syndrome (either ST elevation MI or Non-ST elevation MI) have normal or near normal coronary arteries but they are not included in this group. &nbsp;",
"     </li>",
"     <li>",
"      Chest pain in these patients may be similar to angina or atypical. There is no definite test for diagnosis of cardiac syndrome X and it is a diagnosis of exclusion. Usually, this diagnosis is established by demonstration of normal epicardial coronary arteries on a coronary angiogram in a patient with anginal symptoms and a positive stress test.",
"     </li>",
"     <li>",
"      Although most patients with cardiac syndrome X and stable symptoms have an excellent prognosis, some patients are at increased cardiovascular risk.",
"     </li>",
"     <li>",
"      Therapy is tailored to individual patient. Reassurance is key as patients with stable symptoms have a benign course. Beta blockers seem to be effective in decreasing frequency and severity of symptoms. Sublingual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      may also help symptoms in some patients but calcium channel blockers are not very effective.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/1\">",
"      Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002; 346:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/2\">",
"      Panza JA. Myocardial ischemia and the pains of the heart. N Engl J Med 2002; 346:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/3\">",
"      Cannon RO 3rd. The sensitive heart. A syndrome of abnormal cardiac pain perception. JAMA 1995; 273:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/4\">",
"      Rosen SD, Uren NG, Kaski JC, et al. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation 1994; 90:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/5\">",
"      Kemp HG, Kronmal RA, Vlietstra RE, Frye RL. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 1986; 7:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/6\">",
"      Jong P, Mohammed S, Sternberg L. Sex differences in the features of coronary artery disease of patients undergoing coronary angiography. Can J Cardiol 1996; 12:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/7\">",
"      Sullivan AK, Holdright DR, Wright CA, et al. Chest pain in women: clinical, investigative, and prognostic features. BMJ 1994; 308:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/8\">",
"      Daly C, Clemens F, Lopez Sendon JL, et al. Gender differences in the management and clinical outcome of stable angina. Circulation 2006; 113:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/9\">",
"      Kaski JC, Rosano GM, Collins P, et al. Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol 1995; 25:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/10\">",
"      Panza JA, Laurienzo JM, Curiel RV, et al. Investigation of the mechanism of chest pain in patients with angiographically normal coronary arteries using transesophageal dobutamine stress echocardiography. J Am Coll Cardiol 1997; 29:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/11\">",
"      Merz CN, Kelsey SF, Pepine CJ, et al. The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. J Am Coll Cardiol 1999; 33:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/12\">",
"      Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 2006; 166:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/13\">",
"      Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol 1994; 74:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/14\">",
"      Roe MT, Harrington RA, Prosper DM, et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation 2000; 102:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/15\">",
"      Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 2002; 288:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/16\">",
"      Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/17\">",
"      Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med 1999; 341:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/18\">",
"      Da Costa A, Isaaz K, Faure E, et al. Clinical characteristics, aetiological factors and long-term prognosis of myocardial infarction with an absolutely normal coronary angiogram; a 3-year follow-up study of 91 patients. Eur Heart J 2001; 22:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/19\">",
"      Kaski JC, Crea F, Nihoyannopoulos P, et al. Transient myocardial ischemia during daily life in patients with syndrome X. Am J Cardiol 1986; 58:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/20\">",
"      Buchthal SD, den Hollander JA, Merz CN, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000; 342:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/21\">",
"      Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/22\">",
"      Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001; 141:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/23\">",
"      Masci PG, Laclaustra M, Lara JG, Kaski JC. Brachial artery flow-mediated dilation and myocardial perfusion in patients with cardiac syndrome X. Am J Cardiol 2005; 95:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/24\">",
"      Atmaca Y, Ozdemir AO, Ozdol C, et al. Angiographic evaluation of myocardial perfusion in patients with syndrome X. Am J Cardiol 2005; 96:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/25\">",
"      Mukerji B, Mukerji V, Alpert MA, Selukar R. The prevalence of rheumatologic disorders in patients with chest pain and angiographically normal coronary arteries. Angiology 1995; 46:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/26\">",
"      Al Suwaidi J, Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med 1999; 131:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/27\">",
"      Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000; 109:181.",
"     </a>",
"    </li>",
"    <li>",
"     Maseri, A. Ischemic Heart Disease, Churchill Livingstone, United Kingdom 1995. p.507.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/29\">",
"      Lanza GA, Manzoli A, Pasceri V, et al. Ischemic-like ST-segment changes during Holter monitoring in patients with angina pectoris and normal coronary arteries but negative exercise testing. Am J Cardiol 1997; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/30\">",
"      Cannon RO 3rd, Camici PG, Epstein SE. Pathophysiological dilemma of syndrome X. Circulation 1992; 85:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/31\">",
"      Fragasso G, Rossetti E, Dosio F, et al. High prevalence of the thallium-201 reverse redistribution phenomenon in patients with syndrome X. Eur Heart J 1996; 17:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/32\">",
"      Anselmi M, Golia G, Marino P, et al. Comparison of left ventricular function and volumes during transesophageal atrial pacing combined with two-dimensional echocardiography in patients with syndrome X, atherosclerotic coronary artery disease, and normal subjects. Am J Cardiol 1997; 80:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/33\">",
"      Cannon RO 3rd, Bonow RO, Bacharach SL, et al. Left ventricular dysfunction in patients with angina pectoris, normal epicardial coronary arteries, and abnormal vasodilator reserve. Circulation 1985; 71:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/34\">",
"      Nihoyannopoulos P, Kaski JC, Crake T, Maseri A. Absence of myocardial dysfunction during stress in patients with syndrome X. J Am Coll Cardiol 1991; 18:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/35\">",
"      Lee DC, Simonetti OP, Harris KR, et al. Magnetic resonance versus radionuclide pharmacological stress perfusion imaging for flow-limiting stenoses of varying severity. Circulation 2004; 110:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/36\">",
"      Lanza GA, Buffon A, Sestito A, et al. Relation between stress-induced myocardial perfusion defects on cardiovascular magnetic resonance and coronary microvascular dysfunction in patients with cardiac syndrome X. J Am Coll Cardiol 2008; 51:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/37\">",
"      Bugiardini R, Manfrini O, Pizzi C, et al. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 2004; 109:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/38\">",
"      Bugiardini R, Bairey Merz CN. Angina with \"normal\" coronary arteries: a changing philosophy. JAMA 2005; 293:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/39\">",
"      Wiedermann JG, Schwartz A, Apfelbaum M. Anatomic and physiologic heterogeneity in patients with syndrome X: an intravascular ultrasound study. J Am Coll Cardiol 1995; 25:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/40\">",
"      Cannon RO 3rd, Watson RM, Rosing DR, Epstein SE. Angina caused by reduced vasodilator reserve of the small coronary arteries. J Am Coll Cardiol 1983; 1:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/41\">",
"      Rosano GM, Kaski JC, Arie S, et al. Failure to demonstrate myocardial ischaemia in patients with angina and normal coronary arteries. Evaluation by continuous coronary sinus pH monitoring and lactate metabolism. Eur Heart J 1996; 17:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/42\">",
"      Opherk D, Zebe H, Weihe E, et al. Reduced coronary dilatory capacity and ultrastructural changes of the myocardium in patients with angina pectoris but normal coronary arteriograms. Circulation 1981; 63:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/43\">",
"      Camici PG, Gistri R, Lorenzoni R, et al. Coronary reserve and exercise ECG in patients with chest pain and normal coronary angiograms. Circulation 1992; 86:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/44\">",
"      Pepine CJ, Balaban RS, Bonow RO, et al. Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 1: diagnosis of stable ischemia and ischemic heart disease. Circulation 2004; 109:e44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/45\">",
"      Lichtlen PR, Bargheer K, Wenzlaff P. Long-term prognosis of patients with anginalike chest pain and normal coronary angiographic findings. J Am Coll Cardiol 1995; 25:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/46\">",
"      Radice M, Giudici V, Marinelli G. Long-term follow-up in patients with positive exercise test and angiographically normal coronary arteries (syndrome X). Am J Cardiol 1995; 75:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/47\">",
"      Cox ID, Schwartzman RA, Atienza F, et al. Angiographic progression in patients with angina pectoris and normal or near normal coronary angiograms who are restudied due to unstable symptoms. Eur Heart J 1998; 19:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/48\">",
"      Pitts WR, Lange RA, Cigarroa JE, Hillis LD. Repeat coronary angiography in patients with chest pain and previously normal coronary angiogram. Am J Cardiol 1997; 80:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/49\">",
"      Sicari R, Palinkas A, Pasanisi EG, et al. Long-term survival of patients with chest pain syndrome and angiographically normal or near-normal coronary arteries: the additional prognostic value of dipyridamole echocardiography test (DET). Eur Heart J 2005; 26:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/50\">",
"      Larsen AI, Galbraith PD, Ghali WA, et al. Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 2005; 95:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/51\">",
"      Kaski JC, Valenzuela Garcia LF. Therapeutic options for the management of patients with cardiac syndrome X. Eur Heart J 2001; 22:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/52\">",
"      Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). Circulation 2004; 109:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/53\">",
"      Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/54\">",
"      Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol 1999; 84:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/55\">",
"      Bugiardini R, Borghi A, Biagetti L, Puddu P. Comparison of verapamil versus propranolol therapy in syndrome X. Am J Cardiol 1989; 63:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/56\">",
"      Fragasso G, Chierchia SL, Pizzetti G, et al. Impaired left ventricular filling dynamics in patients with angina and angiographically normal coronary arteries: effect of beta adrenergic blockade. Heart 1997; 77:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/57\">",
"      Madaric J, Bartunek J, Verhamme K, et al. Hyperdynamic myocardial response to beta-adrenergic stimulation in patients with chest pain and normal coronary arteries. J Am Coll Cardiol 2005; 46:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/58\">",
"      Masumoto A, Mohri M, Takeshita A. Three-year follow-up of the Japanese patients with microvascular angina attributable to coronary microvascular spasm. Int J Cardiol 2001; 81:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/59\">",
"      Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 1994; 23:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/60\">",
"      Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity. Circulation 2004; 109:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/61\">",
"      Cannon RO 3rd, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/62\">",
"      Cox ID, Hann CM, Kaski JC. Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J 1998; 19:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/63\">",
"      Rosano GM, Peters NS, Lefroy D, et al. 17-beta-Estradiol therapy lessens angina in postmenopausal women with syndrome X. J Am Coll Cardiol 1996; 28:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/64\">",
"      Roqu&eacute; M, Heras M, Roig E, et al. Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. J Am Coll Cardiol 1998; 31:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/65\">",
"      Eriksson BE, Tyni-Lenn&egrave; R, Svedenhag J, et al. Physical training in Syndrome X: physical training counteracts deconditioning and pain in Syndrome X. J Am Coll Cardiol 2000; 36:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/66\">",
"      B&oslash;tker HE, Sonne HS, Schmitz O, Nielsen TT. Effects of doxazosin on exercise-induced angina pectoris, ST-segment depression, and insulin sensitivity in patients with syndrome X. Am J Cardiol 1998; 82:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/67\">",
"      Galassi AR, Kaski JC, Pupita G, et al. Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X. Am J Cardiol 1989; 64:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/68\">",
"      Rosen SD, Lorenzoni R, Kaski JC, et al. Effect of alpha1-adrenoceptor blockade on coronary vasodilator reserve in cardiac syndrome X. J Cardiovasc Pharmacol 1999; 34:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/69\">",
"      Elliott PM, Krzyzowska-Dickinson K, Calvino R, et al. Effect of oral aminophylline in patients with angina and normal coronary arteriograms (cardiac syndrome X). Heart 1997; 77:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/70\">",
"      Yoshio H, Shimizu M, Kita Y, et al. Effects of short-term aminophylline administration on cardiac functional reserve in patients with syndrome X. J Am Coll Cardiol 1995; 25:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/42/5802/abstract/71\">",
"      Lanza GA, Sestito A, Sgueglia GA, et al. Effect of spinal cord stimulation on spontaneous and stress-induced angina and 'ischemia-like' ST-segment depression in patients with cardiac syndrome X. Eur Heart J 2005; 26:983.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1479 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5802=[""].join("\n");
var outline_f5_42_5802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H454739\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RELATIONSHIP TO VARIANT ANGINA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Stable angina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Non-ST elevation ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Stress-induced cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nitrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ACE inhibitors and statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Imipramine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Physical training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Alpha blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Aminophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Spinal cord stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454739\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1479\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1479|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/15/20733\" title=\"table 1\">",
"      Card synd X variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=related_link\">",
"      Chest pain of esophageal origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=related_link\">",
"      Electrocardiographic changes during exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=related_link\">",
"      New therapies for angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_42_5803="Types of effector systems";
var content_f5_42_5803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effector systems",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Adenylyl cyclases - cAMP",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       Phospholipases C and A",
"       <sub>",
"        2",
"       </sub>",
"       - IP",
"       <sub>",
"        3",
"       </sub>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Guanylate cyclase - cGMP",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Potassium channels",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Calcium channels",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Others?",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Effector systems for G protein coupled receptors. The enzymes adenylyl cyclase, phospholipase C and guanylate cyclase cause the production of specific second messengers, such as cAMP, IP3, or cGMP, which then mediate intracellular effects. Other effector systems, such as those involving ion channels, are more closely regulated by direct coupling with their G-proteins. Effector systems of some GPCRs are unknown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5803=[""].join("\n");
var outline_f5_42_5803=null;
var title_f5_42_5804="Hydroxychloroquine dosing";
var content_f5_42_5804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested hydroxychloroquine dosing for treatment of rheumatic diseases in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Ideal body weight (kg)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and daily schedule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;60",
"       </td>",
"       <td>",
"        400 mg daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        57-61",
"       </td>",
"       <td>",
"        200 mg one day per week (eg, Sunday), and 400 mg daily for the other 6 days of the week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        53-56",
"       </td>",
"       <td>",
"        200 mg two days per week (eg, Saturday, Sunday), and 400 mg daily for the other 5 days of the week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        49-52",
"       </td>",
"       <td>",
"        200 mg three days per week (eg, Monday, Wednesday, Friday), and 400 mg daily for the other 4 days of the week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        44-48",
"       </td>",
"       <td>",
"        400 mg three days per week (eg, Monday, Wednesday, Friday), and 200 mg daily for the other 4 days of the week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40-43",
"       </td>",
"       <td>",
"        400 mg two days per week (eg, Saturday, Sunday), and 200 mg daily for the other 5 days of the week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36-39",
"       </td>",
"       <td>",
"        400 mg one day per week (eg, Sunday), and 200 mg daily for the other 6 days of the week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31-35",
"       </td>",
"       <td>",
"        200 mg daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All doses expressed as hydroxychloroquine sulfate. In long term use, the average daily dose may be reduced (see topic). Observe caution in patients with renal or hepatic insufficiency, in whom a reduction in dosage may be necessary.",
"    <div class=\"footnotes\">",
"     * Ideal body weight male (kg) = 50 + (2.3 x height in inches over 5 feet); IBW female (kg) = 45.5 + (2.3 x height in inches over 5 feet). Use patient's actual (total) body weight if it is less than their calculated ideal body weight. A calculator for determining IBW is available to on-line readers. See Calculators, critical care section.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Workshop Report. Canadian Consensus Conference on Hydroxychloroquine. J Rheumatol 2000; 27:2919. Copyright &copy; 2000 Journal of Rheumatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5804=[""].join("\n");
var outline_f5_42_5804=null;
var title_f5_42_5805="Alpha-1 receptor antagonist";
var content_f5_42_5805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Alpha-1 receptor antagonist for BPH*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Dose titration schedule to reduce orthostatic effects",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Terazosin standard (appropriate for most patients)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Days 1 to 3",
"      </td>",
"      <td>",
"       1 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Days 4 to 14",
"      </td>",
"      <td>",
"       2 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Weeks 2 to 6",
"      </td>",
"      <td>",
"       5 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Weeks 7 and thereafter",
"      </td>",
"      <td>",
"       10 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Terazosin rapid (for selected patients)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Days 1 to 3",
"      </td>",
"      <td>",
"       1 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Days 4 to 14",
"      </td>",
"      <td>",
"       2 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Weeks 2 to 3",
"      </td>",
"      <td>",
"       5 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Weeks 4 and thereafter",
"      </td>",
"      <td>",
"       10 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Doxazosin (immediate release)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Days 1 to 3",
"      </td>",
"      <td>",
"       1 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Days 4 to 14",
"      </td>",
"      <td>",
"       2 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Weeks 2 to 6",
"      </td>",
"      <td>",
"       4 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Weeks 7 and thereafter",
"      </td>",
"      <td>",
"       8 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Doxazosin (extended release preparation only)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Days 1 to 21",
"      </td>",
"      <td>",
"       4 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Week 4 and thereafter",
"      </td>",
"      <td>",
"       8 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Uroselective Alpha-1 receptor antagonists",
"       <sup>",
"        [2]",
"       </sup>",
"       &bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Alfuzosin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Initial and maintenance",
"      </td>",
"      <td>",
"       10 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Tamsulosin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Initial and maintenance",
"      </td>",
"      <td>",
"       0.4 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       If inadequate response after 2-4 weeks",
"      </td>",
"      <td>",
"       0.8 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Silodosin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Initial and maintenance",
"      </td>",
"      <td>",
"       8 mg",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BPH: benign prostatic hyperplasia.",
"     <br>",
"      * Titrate dose as tolerated and as needed for effect. Oral administration for all medications is once daily at bedtime. Peak effect of a given dose on BPH symptoms may not be fully evident until 4 to 6 weeks. If therapy is interrupted for three or more days, reinitiate at lowest dose and re-titrate according to schedule.",
"      <br>",
"       &bull; Due to lower risk of orthostatic hypotension and syncope, uroselective agents do not require gradual dose titration. Oral administration for all medications is once daily at bedtime.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     1. Data from: US FDA approved product information accessed at file://dailymed.nlm.nih.gov/dailymed/about.cfm and Lee, M Management of benign prostatic hyperplasia chap 87 in Pharmacotherapy 7th ed Dipiro, JT, Talbert, RL, Yee, GC et al. 2008; McGraw Hill Medical.",
"     <br>",
"      2. Data from: US FDA approved product information accessed at file://dailymed.nlm.nih.gov/dailymed/about.cfm.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5805=[""].join("\n");
var outline_f5_42_5805=null;
var title_f5_42_5806="Cumulative incidence back pain";
var content_f5_42_5806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Back pain: Cumulative incidence age in adolescents and adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 373px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lifetime cumulative incidence of low-back pain for males and females, aged 12 to 41 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Leboeuf-Yde DC, Kyvik KO. At what age does low back pain become a common problem? A study of 29,424 individuals aged 12-41 years. Spine 1998; 23:228.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_42_5806=[""].join("\n");
var outline_f5_42_5806=null;
var title_f5_42_5807="Contents: Plastic surgery";
var content_f5_42_5807=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Plastic surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Plastic surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Breast",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/61/43991\">",
"           Breast cellulitis: Clinical manifestations, diagnosis, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39386\">",
"           Breast reconstruction in women with breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/41/30359\">",
"           Complications of breast and chest wall irradiation for early stage breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/60/5064\">",
"           Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/31/32249\">",
"           Genetic testing for hereditary breast and ovarian cancer syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/0/17418\">",
"           Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/53/34650\">",
"           Management of locoregional recurrence of breast cancer after breast conserving therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30426\">",
"           Management of locoregional recurrence of breast cancer after mastectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40039\">",
"           Nipple inversion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/20/33095\">",
"           Postmastectomy pain syndrome: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/13/10456\">",
"           Principles of burn reconstruction: The female breast",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/14/12521\">",
"           Principles of grafts and flaps for reconstructive surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39657\">",
"           Techniques of breast and chest wall irradiation for early stage breast cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Burns",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/23/34169\">",
"           Burn pain: Principles of pharmacologic and nonpharmacologic management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4326\">",
"           Classification of burns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/58/21417\">",
"           Clinical manifestations, diagnosis, and treatment of burn wound sepsis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/19/23865\">",
"           Epidemiology of burn injuries globally",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/22/15716\">",
"           Evaluating nutritional support for moderate to severe burn patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/19/17716\">",
"           Global costs of fires and burns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/51/22330\">",
"           Hypermetabolic response to severe burn injury: Recognition and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/34/29225\">",
"           Local treatment of burns: Topical antimicrobial agents and dressings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/26/23977\">",
"           Management principles for burns resulting from mass disasters and war casualties",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11401\">",
"           Nutritional demands and enteral formulas for moderate to severe burn patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/20/32070\">",
"           Overview and management strategies for the combined burn trauma patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/7/4215\">",
"           Overview of nutritional support for moderate to severe burn patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/48/9992\">",
"           Prevention of fire and burn injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18409\">",
"           Primary operative management of hand burns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15882\">",
"           Principles of burn reconstruction: Extremities and regional nodal basins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/59/29625\">",
"           Principles of burn reconstruction: Face, scalp, and neck",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/55/20346\">",
"           Principles of burn reconstruction: Overview of surgical procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/59/14263\">",
"           Principles of burn reconstruction: Perineum and genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/13/10456\">",
"           Principles of burn reconstruction: The female breast",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44056\">",
"           Acquired melanocytic nevi (moles)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/25/32151\">",
"           Basic principles of medical lasers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/17/43287\">",
"           Benign pigmented skin lesions other than melanocytic nevi (moles)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33124\">",
"           Closure of minor skin wounds with staples",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/7/18553\">",
"           Closure of skin wounds with sutures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/17/7447\">",
"           Congenital melanocytic nevi and speckled lentiginous nevi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/7/36986\">",
"           Cutaneous complications of conventional chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/61/26585\">",
"           Initial surgical management of melanoma of the skin and unusual sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/51/32567\">",
"           Minor wound preparation and irrigation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12758\">",
"           Nail surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/7/6265\">",
"           Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/53/24410\">",
"           Risk factors for the development of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/20/40264\">",
"           Skin biopsy techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/15/35065\">",
"           Staging work-up and surveillance after treatment of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24266\">",
"           Treatment of hidradenitis suppurativa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42488\">",
"           Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/11/11446\">",
"           Z-plasty",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26264\">",
"           Negative pressure wound therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/14/12521\">",
"           Principles of grafts and flaps for reconstructive surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/32/41478\">",
"           Superficial wound repair with tissue adhesives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/32/14858\">",
"           Surgical management of sternal wound complications",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hand",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/61/18393\">",
"           Overview of finger, hand, and wrist fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/21/27993\">",
"           Overview of hand infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18409\">",
"           Primary operative management of hand burns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/3/32822\">",
"           Surgery for carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/44/19141\">",
"           Trigger finger (stenosing flexor tenosynovitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/40/27270\">",
"           de Quervain's tenosynovitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lymphedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/52/1866\">",
"           Clinical manifestations and diagnosis of lymphedema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/1/33817\">",
"           Prevention and treatment of lymphedema",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pressure ulcers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/20/34120\">",
"           Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/1/1049\">",
"           Prevention of pressure ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/12/37064\">",
"           Treatment of pressure ulcers",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-FF4FB48E4C-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_42_5807=[""].join("\n");
var outline_f5_42_5807=null;
